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ABSTRACT

ADAM10 EXACERBATION OF ALLERGIC DISEASE IS POTENTIALLY
EXPLAINED BY ITS ROLE IN CD23 EXOSOMAL SORTING.
By Joel A. Mathews.
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2011

Director: Daniel H. Conrad, Professor, Department of Microbiology and Immunology

CD23, the natural negative regulator of IgE, has been shown to be involved in
asthma progression through its regulation of IgE. To investigate if its sheddase,
ADAM10, is also involved in asthma progression, three mouse models were utilized; an
IgE/mast cell dependent model, an IgE dependent, mast cell independent model and a
mast cell and IgE independent model. Experimental asthma was then induced in mice
which were selectively deficient for ADAM10 in B cells (ADAM10-/-) and compared to
WT controls. The ADAM-/- mice had decreased signs of asthma, including eosinophilia,
AHR and IgE synthesis in the IgE dependent model compared to LM controls, while with
the IgE independent model there was no significant difference. Thus, CD23Tg and
ADAM10-/- B cell mice have reduced IgE dependent lung inflammation in mouse models
compared to WT controls. As a follow up, ADAM10 was inhibited in WT mice by
intranasal administration of an ADAM10 inhibitor, compared to carrier (DMSO) treated
mice. As with ADAM10-/- mice, inhibition of ADAM10 was only able to control IgE
dependent models. These results thus show that ADAM10 is a possible target in

xviii

controlling IgE dependent allergic disease, possibly as blocking ADAM10 would cause
an increase in CD23 membrane expression.
To better understand how ADAM10 cleaves CD23 we first sought to confirm
previous studies that CD23 is internalized, with the hypothesis that shedding takes place
intracellularly, rather than at the cell surface as previously assumed. Indeed, ADAM10 is
more highly expressed intracellularly than at the cell surface. At 37 ºC, crosslinking
CD23, especially with the anti-stalk mAb 19G5, resulted in extensive CD23
internalization. In addition, the expected increase in soluble CD23 (sCD23) production
when 19G5 was added was blocked by the addition of NH4Cl. NH4Cl is known to block
the progression of the endosomal pathway. These findings thus confirmed our hypothesis
that cleavage of CD23 requires internalization and progression through the endosomal
pathway before it is released into the extracellular space. We further demonstrated that
ADAM10 is not only involved in cleaving CD23, but also in sorting CD23 into
exosomes, as B cells lacking ADAM10 do not incorporate CD23 into exosomes. In
addition, we found that exosomes secreted from the cell contain full length CD23, thus
showing that they could bind IgE/antigen complex and be involved in the known CD23
dependent enhancement of antigen presentation by the injection of IgE/antigen
complexes compared to antigen alone. These results also show that the change in
ADAM10 expression specifically in a B cell could be involved in enhancement of IgE
dependent inflammation.
To determine what signals change ADAM10 expression, ADAM10 promoter
studies were initiated. We found that both IL-21 and anti-CD40 increased ADAM10
promoter activity, while IL-4 and IL-13 had no effect. Overall our data show that

xix

increasing ADAM10 activity and expression leads to increased inflammation and IgE and
is a possible target in controlling IgE dependent diseases.

xx

Introduction
I. Immunoglobulin E
Asthma and allergies are the most common chronic IgE associated diseases. Asthma
attacks are characterized by wheezing, chest tightness, shortness of breath, and coughing
while allergy symptoms include itchy eyes, running nose and sneezing. The prevalence of
these diseases has dramatically increased over the past twenty years. In 2004, in the
United States alone, there were a total of 5.6 million children who had been diagnosed
with an atopic disease (1). The cost is even more astounding. In 1994, for example 12
billion dollars representing 1 to 2% of the total health-care budget was spent for allergic
disease treatment; these numbers have also continued to swell (2).
The underlying cause of asthma and allergies is an increase in allergen specific
IgE. The cross linking of IgE bound to its high affinity receptor (FcεR1) causes the
degranulation of both mast cells and basophils. When a person is first exposure to an
allergen, the allergen is taken up and processed by cells known as APC including
dendritic cells. These cells then migrate to the lymph nodes where they present peptides
derived from the allergen in the context of MHC class II to T cells. This presentation plus
early IL-4 (basophils?) causes the T cells to differentiate into Th2 cells. These Th2 cells
then produce large amounts of IL-13 and IL-4. In parallel the antigen also drains into the
lymph node and is recognized by B cells through B cell antigen receptors (BCR). In this
Th2 environment the B cells are signaled to class switch to IgE producing plasma cells
and the IgE is then bound by mast cells and basophils (3). When the patient undergoes a
secondary exposure, IgE bound to FcεR1, on mast cells and/or basophils will be cross
linked and cause the degranulation of these cells, releasing the mediators common to
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allergies, including histamine, leukotrienes, and prostaglandins. This release is known as
the early phase response and occurs within minutes of antigen exposure. These mediators
can then bind their receptors on smooth muscle cells, blood vessels and epithelial cells
and cause muscle contraction, mucus production and increased vascular permeability. In
addition, several hours after allergen exposure mast cells will release newly synthesized
cytokines and lipid mediators including IL-8, TNFα and LTB4, these mediators will cause
the recruitment of additional immune cells which will exacerbate the response (4). These
cells including eosinophils and Th2 cells (5) and it is this late phase response which is
believed to be the cause of the lasting effects of asthma including airway remolding and
smooth muscle hyperplasia.
A. Discovery of IgE: Originally known as reagin, the idea that IgE could be
causing allergic reactions began to take shape in 1921, in a paper by Prausnitz and
Kustner. They showed that sensitization could be transferred by the transmission of
serum from an allergic patient to a non-allergic patient (6). This work also established
what came to be called the PK test for demonstrating skin-sensitization to allergens in
patients. With this discovery it was shown that the protein/reagin that causes allergies is
found in human serum and over the next 40 years through a variety of experiments
(reviewed in (7)) scientists tried to discover the identity of this protein. With the
development of better serum protein fractionation, the Ishizakas in Denver, CO (8) were
able to isolate a highly enriched reagin preparation and prepared specific antibody against
the purified reagin. Another group in Sweden had discovered a myeloma that did not fit
any of the currently known classes of Ig (9). Exchange of reagents allowed identification
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of a new Ig class, which was named IgE. Finally in 1968, the World Health Organization
recognized that IgE was the fifth class of Ig (10).
B. Class switching to IgE: Class switching in B cells requires two signals, IL4/IL-13 and CD40 signaling. In the pre-B stage the VDJ regions are rearranged to form a
variable region attached to the constant region of either IgM or IgD, and through negative
selection self-reacting B cells are deleted. After activation and trafficking to the germinal
center B cells go through what is known as class-switch recombination (CSR) where they
can switch to IgG, IgE or IgA (or any of their respective subclasses), by splicing out of
sections of the genomic DNA. This occurs when certain signals from outside the cell
activate a promoter that causes the transcription of a sterile transcript. In the case of IgE
this signal is IL-4 or IL-13 signaling through Stat6 as well as NF-κB activated by CD40.
The sterile transcript includes the 140 bp Iε exons along with Cε1-Cε4 of which part is
known as the Sε region. This Sε region forms a DNA-RNA hybrid creating a stable “R
loop” structure. The transcript binds to the G-rich strand, leaving the C-rich strand as a
single strand, which then allows AID to bind and mutate sections of the gene. The
activation of B cells is required for AID to be expressed. Once AID is active it attacks
the C-rich strand changing the C to U. Then through a process involving Uracil
glycosylase and other enzymes, the section between the end of the variable region and the
start of the IgE constant region is spliced out (reviewed in (11)).
In addition to CD40, IL-4 and IL-13 there are other cytokines that either increase
or decrease the synthesis of IgE, through a variety of mechanisms. These include IFN-γ
and α (12), TGF-β (13) and IL-12 (14) which all have an inhibitory effect, while IL-21
(15), IL-10 (16), IL-5 (17), IL-7 (18), IL-6 (19) all increase IgE synthesis.
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C. Anti-IgE and other asthma treatments: Multiple strategies have been tried
to combat the effects of allergens. The most common allergy drugs are either
antihistamines or leukotriene antagonists, such as Benadryl or Singulair respectively (4).
The newest approach is the use of a humanized anti-IgE antibody known clinically as
Omalizumab (Xolair®). This strategy attempts to block IgE from binding to its receptor
on mast cells/basophils. Studies of FcεR1 seem to suggest that it is being produced
constitutively and that with the addition of IgE it controls the loss of FcεR1 from the cell
surface. Thus with the addition of anti-IgE, not only does it remove free IgE from
circulation, but with the decrease in IgE, there is also a corresponding loss of surface
bound FcεR1 on both mast cells and basophils (20). With this loss, upon allergen
exposure there is also decreased degranulation and mediator release. However, this
treatment is not perfect as it is extremely costly and requires repeated treatment because
the synthesis of IgE is not blocked. In addition, anti-IgE therapy is only approved for
those whose levels of IgE fall in the 30 and 700 IU/ml range (21) possibly because when
levels of IgE are to high, the anti-IgE therapy cannot decrease the free IgE to the required
levels. Very little (250 ng/ml) IgE is needed to upregulate FcεR1 surface expression and
it is this down regulation of the receptor that seems to make anti-IgE therapy so effective
(22). Thus, this clearly shows the need for a more cost effective therapy to reduce IgE
serum levels, possibly through decreasing its synthesis.
II. CD23
A. Discovery or CD23: In 1975 while searching for proteins that bound
immunoglobulin on different cell types, Lawrence et al. discovered that lymphocytes
could bind IgE (23). Through further studies, the lymphocyte receptor was shown to have
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Figure 1: Structure of CD23 and ADAM10 – Structure of CD23 (A) Schematic (24),
(B) ribbon (24). (C) Structure of ADAM10 ribbon (25) and (D) schematic.
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a lower affinity then the FcεRI found on mast cells and basophils and was thus named the
low affinity receptor for IgE or FcεRII (reviewed in (26)). Shortly thereafter, while
studying Epstein Barr Virus (EBV) transformed B cells (27) and a protein was found to
be increased following transformation and was called CD23. A second group also found
this same protein and called it BLAST-2, they found it was a marker of cell activation in
B cells (28). Later exchange of monoclonal antibodies confirmed that all three were the
same protein (29) and thus showed that CD23 was the low affinity receptor of IgE,
FcεRII. Cloning of CD23 was accomplished by three independent groups (30-32). This
demonstrated that CD23 was unlike other Ig receptors as it is not a member of the Ig
superfamily, but requires calcium to bind IgE and is a member of the calcium-dependent
(C-type) animal lectin family (33). A quite similar structure was also found for mouse
CD23 (33).
B. Expression, structure and Regulation: CD23 (Shown in Figure 1a and b) is a
type II transmembrane glycoprotein and has two isoforms, which result from alternative
splicing and are known as CD23a and CD23b. In mice CD23a is expressed on follicular
Dendritic cells (FDC) and B cells, while CD23b is found on FDC, gut epithelial cells and
IL-4 activated B cells. In humans, CD23a is found only on B cells while CD23b is found
on a large variety of cells, including IL-4 activated B cells, as well as monocytes,
eosinophils and Langerhans (34). In addition to having different cellular distribution,
CD23a and b are also proposed to have different functions as CD23a mediates
endocytosis of IgE-complexes and CD23b mediates phagocytosis of IgE-complexes
(35;36).
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CD23 contains two important extracellular regions; the lectin head and the coiledcoiled stalk. The stalk region of CD23 contains a tropomyosin-like, periodic heptad
repeat as well as a leucine zipper, allowing it to form a trimerized coiled-coiled stalk at
the cell surface (37). The lectin heads have been shown to bind to the dimeric C3
domains of IgE in a calcium dependent manner (38) at a ratio of 2:1 lectin heads to IgE
(39). CD23 has a dual affinity for IgE; a high affinity (4-10 x 107 M-1) , which is when
CD23 is held in a stabilized trimer, and it is as a trimer that CD23 has the ability to
regulate the synthesis of IgE (40). CD23 when just a monomer has a much lower affinity
(4-10 x 106 M-1) (34). The leucine zipper portion of the stalk is essential for holding
CD23 in a trimer and positioning the lectin heads in the correct conformation (41). CD23
is often referred to by its stability, stabilizing antibodies decrease cleavage, destabilizing
antibodies increase cleavage. When CD23 is destabilized, with an anti-stalk mAb, it was
found that although the lectin heads are not in close proximity the cytoplasmic tails are
still held together. This suggests that CD23 is pre-associated as a trimer at the cell surface
and although the trimer can be destabilized, the N-terminus domain stays associated
under all conditions (40).
CD23 expression is also regulated by the addition of cytokines and its ligand.
High levels of IgE correlate with increased CD23 surface levels (42), however this is not
due to changes in mRNA levels or protein synthesis, but decreased cleavage (43).
Cytokines however, do change CD23s synthesis, with both IL-4 and IL-13 increasing
CD23 levels in the human system (44). The finding that CD23 and its ligand IgE are
increased by IL-4 supports the notion that CD23 is a natural negative regulator of IgE
production. In addition, LPS and CD40 signaling also increases its expression (45). In
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contrast to IL-4, IFN-γ downregulates both CD23a and b on B cells while have the
opposite effect on FDC (46). As will be discussed later, this trend seems to show that
CD23 is potentially involved in enhancing the initial IgE response, but then negatively
regulates later responses.
C. Cleavage. Shortly after its discovery CD23 was also shown to be found in the
supernatants of lymphocytes and to retain its IgE binding ability (39). This soluble
fraction was termed soluble CD23 (sCD23). As a membrane bound form CD23 in mice is
45 kD and in human 48 kD. After cleavage sCD23 fragments of 37 and 28 kD and 37,
33, 25 and 12 in humans and mice systems respectively are found in the extracellular
space (reviewed in (34)). These fragments contain varying amounts of the stalk and thus
are mostly found as monomers and have a low affinity in the (~10-6) range for IgE.
Through the use of a variety of inhibitors it was shown that CD23 was cleaved primarily
by a membrane-anchored metalloprotease of approximately 62 kD (47). Eventually in
2006 this protease was identified as a disintegrin and metalloprotease 10 (ADAM10)
(48;49) and later confirmed by knockout studies in 2010 (50). These studies found that
ADAM10 was responsible for the initially cleavage and that other soluble proteases are
responsible for the further fragmentation (48). This work thus suggests that blocking
ADAM10 could potentially decrease IgE synthesis.
D. Involvement in IgE regulation/asthma. Studies with CD23 knockout
(CD23-/-) mice had seeming conflicting results. The first CD23 deficient mouse was
produced on a mixed background with CD23-/- embryonic stem cells from a 129 mouse
being injected into a C57BL/6 mouse. These mice had normal immune development and
were found to have no increase in antigen specific IgE after immunization with an
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antigen/adjuvant (51). A second mouse created on a pure C57BL/6 background found a
different phenotype as the mice had a two-fold increase in basal level of serum IgE
compared to wild type (WT) (52). In addition, when the CD23-/- mice on a pure
C57BL/6 background were subjected to a mouse asthma model they had increased
eosinophilia, airway hyperresponsiveness and antigen specific IgE levels compared to
WT (53). The disparity between these reports is potentially explained by the difference
in mouse background because 129 mice are known to have high levels of IgE (54).
Additionally, several CD23 transgenic (CD23Tg) mice have also been reported. The first
report discussed their findings using two separate transgenic mice strains, where CD23 or
sCD23 were overexpressed using the Thy1 promoter on T-cells. In the study with sCD23
they found that, although sCD23 levels were elevated (only relative measurements were
used), IgE levels were unchanged compared to WT. This suggested that, at least in the
mouse, sCD23 has no effect on IgE (55). However, this finding could be attributed to
either inadequate production of sCD23 or because it was not produced in the correct
environment. With mouse that had overexpression of membrane bound CD23 the authors
found no decrease in basal level IgE, however a reduction in IgE levels in response to an
antigen/adjuvant challenge was observed (55). A second CD23Tg mouse was also
created with expression being controlled by the major histocompatibility complex (MHC)
class I promoter combined with the Ig enhancer; founders were selected that maximally
overexpressed CD23 on B cells. In this study, the authors found a decrease in IgE as well
as IgG1, at both basal level and following antigen/adjuvant challenge, compared to WT
(56). These mice also had a decrease in other atopic signs including eosinophilia and
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Figure 2 – Model of CD23 regulation of IgE. This model as proposed by Hannah Gould
(24). In (A) she shows potentially how sCD23 can increase IgE production. However,
with increased IgE, it will bind CD23 on the cell surface preventing its cleavage and
negatively regulate further IgE production. (B) Shows that with large amounts of sCD23
all the membrane IgE and CD21 on the cell surface would be cross linked and lead to
increased IgE production. (C) Shows the overall model that with CD23 binding of IgE or
an anti-lectin mAb, synthesis of IgE is negatively regulated, while with the cleavage of
CD23 this regulation is lost.
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airway hyperresponsiveness following asthma induction (53). These mouse strains clearly
show that CD23 regulates IgE synthesis in the context of asthma and that stabilization is
a possible target for therapy. However, in a clinical trial in allergy patients who were
injected with a humanized anti-CD23 (Lumiliximab), no change in allergy symptoms
were seen. Lumiliximab caused only a 40% drop in serum IgE (57), which is not
sufficient for clinical efficacy. But this trial did show that CD23 could be targeted to
make other therapies more effective. Of note, lumiliximab is currently being tried as an
add-on therapy in B cell chronic Lymphocytic Leukemia (58) and was well tolerated and
in initial trials seemed to have some efficacy.
Overall a model that focuses on how CD23 controls IgE production in the human
system has been proposed by Hannah Gould and is shown in Figure 2 (24). She proposes
that when sCD23 is released from the cell while still a trimer it can cross-link CD21 and
membrane bound IgE. This cross-linking serves as a positive feedback and leads to
increased IgE production. Conversely as IgE levels increase, it will bind to membrane
bound CD23, preventing its cleavage. Additionally this CD23 bound IgE can be crosslinked to membrane bound IgE by antigen and this cross-linking will then negatively
regulate further production of IgE. Although this model works for findings in the human
system, it is not supported by findings in the mouse system, where CD23 lacks the ability
to bind CD21. Herein we suggest a different model.
E. Involvement in antigen processing and presentation: The concept that the
aggregation of antibodies can increase uptake and processing of antigen has been known
for over a century (59). In connection with this, if antigen bound to an antibody is
injected in vivo there is over a 1000-fold increase in antigen specific antibody response
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(reviewed in (60)). This is also true for IgE and is completely dependent on CD23
expression, as this enhancement is not seen in mice treated with anti-lectin mAbs or mice
deficient in CD23 (61). Gustavsson et al. additionally showed that this effect is
specifically caused by B cell CD23 as CD23-/- mice that where injected with bone
marrow derived from WTs still display the enhancement (62). In addition, Getahun et al.
have also shown that when mice are injected with IgE-antigen complexes there is also an
increase in antigen specific T cell proliferation (63). In combination with studies in
CD23-/- mice these studies demonstrate that CD23 could potentially be involved in
enhancing the initial response, but later after IgE reaches a certain threshold it serves to
decrease the production.

III. ADAM10
A. Discovery of ADAM10: ADAM10 (Shown in Figure 1c and d) is a member of
a large family of proteases which presently includes 40 members (http://people.virginia
.edu/~jw7g/Table_of_the_ ADAMs.html). These proteases are similar to MMP and
ADAMTS, but differ in that ADAM family members perform their function while being
membrane bound. ADAM10 was first discovered in 1996 in Drosophila, because of its
importance in development, through mutation studies and was named kuzbanian (kuz)
(64). ADAM10 was also found to be important in the mammalian system as mice
deficient of ADAM10 die in utero at E9.5 (65). This is because of ADAM10 importance
in notch signaling. ADAM10 is also involved in T cell (66) as well as MZ B cell
development (50).
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B. Structure: ADAM10 is a multidomain transmembrane protein containing the
following domains protease, disintegrin and cysteine-rich (67). Through use of
recombinant molecules missing the protease domain, the major site of substrate
interaction was found to be in the disintegrin and cysteine-rich domains (25). Janes et al.
(25) additionally found that the disintegrin domain is very similar in structure to two
other proteins, disintegrins trimestatin and blood coagulation inhibitor from snake venom.
The cysteine-rich domain is unique as it contains a novel /β fold. They additionally
showed that the two domains are tightly packed together and held together by disulfide
bonds. The cysteine-rich domain was named because of its high concentration of
cysteine amino acids and the spacing of these domains in ADAM10 was found to be
similar to ADAM17, which might partially explain why these two proteases have
overlapping in substrate specificities; however the spacing of the cysteines is different
from all other mammalian ADAMs including 9, 12 and 15. Finally Janes et al. showed
that the cysteine-rich domain contains a surface pocket made up of acidic resides and that
when these resides are mutated, ADAM10 loses its substrate-recognition ability (25).
C. Substrates: ADAM10 has been discovered to cleave many proteins and a list
can be found in a recent review (68). Some that will be mentioned later are C44 (69), L1
(70), EGF (71), CD23 (48;49) and Notch. As mentioned earlier, when ADAM10 is
genetically deleted mice die in utero at E9.5. This is attributed to the loss of Notch
signaling. Notch is the best characterized of all ADAM10 substrates. As Gibb et al. (50)
recently reported this signaling is also important in B cell development. There have been
four different Notch proteins discovered, but only Notch 1 and 2 have known biological
activity. These proteins interact with their ligands, including Delta 1 and Jagged, in both
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cis and trans, with cis interaction being inhibiting, while trans interaction is activating.
When Notch and its ligand interact it causes a change in conformation and allows
ADAM10 to interact and cleave at the S2 cleavage site. This cleavage further changes
the conformation of Notch and allows γ-secretase to interact and cleave Notch at the S3
site. This cleaves the intracellular domain known as NICD, which is released and
translocates to the nucleus where it acts as a transcription factor. Such genes affected
include CD21 in B cells, Hes5, and Deltex-1 (reviewed in (72))
D. Exosomes: The cleavage of plasma membrane bound proteins and their
subsequent release from the cell is described as ectodomain shedding. Historically, this
was believed to be a cell surface process. However, recently a second mechanism was
discovered, involving the release of proteins after their internalization and subsequent
trafficking through the endosomal pathway to multivesicular bodies (MVB) (73). In the
MVB, the proteins can interact with their sheddase and be cleaved and released or be
sorted into exosomes and released as full length proteins. Exosomes are small, 30-100
nm, membrane containing vesicles that are released by a wide variety of cells. As they
have high expression of major histocompatibility complexes (MHC) molecules they have
been investigated as cell free transporters of cancer antigens in cancer immunotherapy
treatments (74). Exosomes released from B cells have also been extensively studied. B
cell derived exosomes express integrins (75), which allow them to bind to the cell surface
of other cells including T cells. Also due to their expression of MHC molecules they can
present antigen to T cells. They have also been shown to transport antigens, including
peptides derived from allergen between APCs (reviewed in (76)). B cell exosome
secretion is also increased upon activation with CD40L (77) and interaction with T cells
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(78). However, the secretion of exosomes by cells and the mechanism that controls the
sorting of proteins into exosomes are still poorly understood.
Initially ADAM10 dependent cleavage was believed to take place at the cell
surface; however, high levels of ADAM10 are observed in the Golgi and the endosomal
regions of the cell. Indeed, two ADAM10 substrates, CD44 and the adhesion molecule
L1 (CD171), were recently shown to be released in from the cell in the context of
exosomes (79). This indicates an alternative mechanism for ADAM10 substrate
trafficking and cleavage.
E. Involvement of ADAM10 and other metalloproteases in asthma: In a pilot
study in 2004, twelve atopic asthmatic subjects were injected with 5 mg of the broad
spectrum inhibitor Marimastat twice daily for 3 weeks followed by a 6 week washout
period (80). Marimastat was shown to decrease hyperresponsiveness as well as sputum
inflammatory cells compared to placebo. In addition, using animals where MMPs have
been knockout, several MMP have been shown to be involved in experimental asthma
progression (reviewed in (81)). These studies highlight the role of proteolysis in asthma.
Although, ADAM10 has never been studied for its ability to regulate the progression of
asthma, it has been found to be highly expressed in the lungs of asthmatics (82) as well as
to be increased at the mRNA level after the induction of a mid-length experimental
asthma model (83). These studies thus show that ADAM10 potentially could be involved
in asthma as well.
F. Regulation of ADAM10 activity: ADAM10 is first expressed as a zymogen,
and its prodomain is then removed by a furin protease while in the Golgi and results in an
active protein (84). After activation, ADAM10 can be regulated in a variety of ways (A)
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by tissue inhibitors of metalloproteases (TIMP) including TIMP1 and TIMP3 (85). (B)
ADAM10 activity is increased by the influx of calcium into the cell (modeled by the use
of ionomycin). This increased activity is dependent on ADAM10’s intracellular domain,
since removal of this domain blocked the calcium effect (86). However, the change
induced by calcium did not change the cellular distribution of ADAM10 or increase the
removal of the prodomain. Calcium is thought to modify the conformation of the
intracellular domain thereby increasing substrate binding and cleavage (86). (C)
Activation of the ADAM10 promoter. This has already been demonstrated with retinoic
acid (108). Future studies may demonstrate other agents that modify ADAM10
expression in this manner.
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IV. Dissertation objectives: In two separate reports it was shown that ADAM10 is the
sheddase of CD23 (48;49). In addition for many years there has a theory regarding the
stability of CD23. This is based on the observation that antibodies against the stalk region
increase cleavage of CD23 and IgE production (42;87), while antibodies against the
lectin head region of CD23 decrease cleavage and IgE production (42). In addition, it has
been shown through the use of CD23-/- mice, as well as the injection of anti-lectin
antibodies and CD23Tg, that increased CD23 correlates with decreased signs of
experimental asthma in IgE dependent models (53). The first part of this dissertation is
dedicated to determining whether ADAM10 has a role in experimental allergic asthma,
using a B cell specific ADAM10 knockout and the administration of ADAM10 inhibitors
directly to the lung.
In addition, although CD23 is known to be cleaved by ADAM10, nothing is
known about how they interact or where in the cell the interaction of ADAM10 and
CD23 takes place. In the second part of this dissertation, we sought to answer this
question, and determine how stability affects the interaction. In connection with this we
sought to determine what signals increase ADAM10 expression. Finally in connection
with our findings in mice we sought to determine the effect of ADAM10 activity on IgE
production and B cell proliferation through the use of siRNA and ADAM10 selective
inhibitors.
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Material and methods:
I. Reagents, antibodies, mice.
FITC-rat anti-mouse CD23 (clone B3B4), an anti-lectin mAb, was obtained from BD
PharMingen (San Diego, CA). Rat anti-mouse CD23 (clone 2H10) (40), an anti-CD23
lectin mAb, 19G5 (40), an anti-CD23 stalk mAb and C0H2, a rat IgG2, used as an
isotype control mAb, were all purified from tissue culture supernatant as previously
described (88). Monoclonal mouse IgE (mIgE-DNP) (89) from H1-DNP- -26 was
purified from tissue culture supernatant as described previously (40). JW8 (humanized
IgE anti-NIP) was purified from culture supernatant. Rabbit anti-ADAM10 was obtained
from Chemicon (Billerica, MA). Rabbit anti human CD23 was created in our lab by
injecting recombinant trimeric human CD23 (lz-CD23) (90) containing the extracellular
region of human CD23 into rabbits. The antibodies were then purified on a Protein G
sepharose (Sigma) column. Mouse lz-CD23 (extracellular CD23 held in a trimer by the
addition of a leucine zipper motif) and fragments, and yellow fluorescent protein (YFP)
tagged mouse CD23 were created as previously described (40;90). The ADAM10
hydroxamate inhibitors, INC008765 ((1R,3S,4S)-3-(hydroxycarbamoyl)-4-(4phenylpiperidine-1-carbonyl) cyclohexyl pyrrolidine-1-carboxylate) (Figure 3a) and
INC009588 (91), were synthesized by the Incyte Corporation (Wilmington, DE). These
inhibitors are selective for ADAM10 as they require at least 5 fold higher concentrations
to inhibit MMP12 and at least 20 fold to inhibit any other enzymes including ADAM17
(91). GI254023X ((2R,3S)-3-(Formyl-hydroxyamino)-2-(3-phenyl-1-propyl) butanoic
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Figure 3: Chemical structure of inhibitors. (A) Structure of Incyte ADAM10 inhibitor
(INC008765). (B) Structure of Glaxo ADAM10 inhibitor (92)
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acid [(1S)-2,2-dimethyl-1-methylcarbamoyl-1-propyl] amide) (92) is shown in Figure 3b
and was provided by Neal Broadway at GlaxoSmithKline (Stevenage SG1 2NY, UK) and
will be referred to as Glaxo ADAM10 inhibitor in the paper. Both the Glaxo and Incyte
inhibitors are competitive inhibitors and bind the active site of ADAM10, thus blocking
its ability to cleave its substrates including CD23 (49), it is also believed at least for the
Glaxo ADAM10 inhibitor that the phenyl group can also bind the S1’ pocket of
ADAM10. This pocket is believed to constitute a large portion of the protease’s substrate
recognition domain. INC000129, Incyte ADAM17 inhibitor was also used to show the
inhibitors were selective for ADAM10.
HA-mADAM10-pcDNA3.1 (86) was a gift from Carl Blobel at Cornell
University. HA-hADAM10-pUK-BK-C (92) was a gift from Uwe Konietzko at the
University of Zurich. Dominant Negative ADAM10 lacks its Metalloproteinase domain
and consists of the leader sequence and part of the prodomain linked to the disintegrin,
cysteine-rich, transmembrane, and cytoplasmic domains and was produced as described
(93) and inserted into p-Tracer. Rabbit anti-HA was purchased from Novus Biologicals
(Littleton, CO). Goat anti-Rabbit-HRP was obtained from Southern Biotech
(Birmingham, Alabama). A humanized anti-CD23 lectin (IDEC-152) (94) was a gift from
Marylin Kehry at Biogen-Idec (San Diego, CA). Ez-link-sulfo-NHS-biotin (NHS-biotin)
was purchased from Pierce (Rockford, IL). Anti-H2-I/Adβ (5K43) was purchased from
Santa Cruz biotech (Santa Cruz, CA). Mouse IL-4 was a gift from Bill Paul (NIH).
Rabbit anti-calnexin (BD) (marker of endoplasmic reticulum), goat anti-EEA1 (Santa
Cruz) (marker of early endosome), Rabbit anti-Rab11 (Invitrogen) (marker of recycling
endosome/MVB), and Mouse anti-LAMP1 (marker of lysosome) (University of Iowa

22

Hybridoma bank) were all gifts from Dr. Jason Carylon (VCU). DyLight 649-Donkey
anti-Rabbit IgG and DyLight 649-Goat anti-mouse IgG were purchased from BioLegend
(San Diego) and APC-Rabbit anti-Goat IgG is from BD. PE-Goat anti-rabbit IgG and
FITC-Goat anti-rat IgG were also purchased from BioLegend. Recombinant mouse
ADAM10 (rADAM10) was purchased from R&D Bioscience (Minneapolis, MN).
Chicken Ovalbumin (OVA) and Imject Alum Adjuvant were purchased from Sigma (St.
Louis, MO) and Pierce (Rockford, IL), respectively. DNP-Ova was prepared by as
explained previously (95).
CD23 transgenics were described previously (56) and have been backcrossed 12
generation onto a BALB/C background. Littermates negative for the transgene were used
as controls. CD19-Cre+/-ADAM10fl/fl mice on a C57BL/6 background (50) were
described previously, and were also used as a source of ADAM10 deficient B cells and
will be referred to as ADAM10-/- throughout this paper, littermates that were negative
for Cre expression were used as WT controls. Female C57BL/6J and BALB/C mice were
purchased from Jackson Laboratory (Bar Harbor, ME) and used in the inhibitor studies.
Female mice ages 8-12 weeks were used in the experiments. All mouse protocols were
approved by the Virginia Commonwealth University Institutional Animal Care and Use
committee.
II. Mouse Asthma inductions.
Experimental asthma was induced using three different models, two IgE dependent
models and one IgE/mast cell independent model. The first model (Figure 4a) was
previously described (96) and was shown to be dependent on both mast cells and IgE
using W/Wsh and FcεRI mice respectively and will be referred to as model A. The mice
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Figure 4. Mouse asthma models. (A) Mast cell/IgE dependent model. This model is a
modified model developed by the Dr. Stephen Galli laboratory of their original model
published in (97) used in Figures 15-17 and is called Model A in text. Mice were injected
IP with OVA on days 1, 3, 5 and 7. Then on days 22, 25 and 28 mice were challenged IN
with OVA and sacrificed on day 29. (B) Mast cell/IgE independent model. This model
was used in Figure 18 and 19 and is called Model C in text. Mice were injected with
OVA/Alum on days 1 and 8. Then ever day from 14-10 mice were challenged by giving
aerosolized OVA (1% in PBS) for 45 minutes. Then on day 21 mice were sacrificed.
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Figure 5: IgE dependent and mast cell independent mouse asthma model. This
model was used in Figures 20 and 21 and will be called Model B in the text. Adopted
from (98). Mice were injected IP on days 0 and 14 with OVA/Alum. Mice were then
challenged with aerosolized OVA (1% in PBS) on days 19, 22 and 27. Mice were then
sacrificed on day 29.
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were initially bleed on day 0 to determine baseline IgE levels, mice were sensitized by
the intraperitoneal injection of 50 μg of OVA in 100 μl of (0.15 M) saline on days 1,3,5
and 9. Then 15 days later the mice were challenged intranasally with 200 μg of OVA in
20 μl of PBS and again on day 25 and 28 (Shown in Figure 4a). Finally 18 hours after
the final OVA challenge, airway resistance was measured using the Flexivent system
(Scireq, Montreal, Canada). Briefly, mice were anesthetized by intraperitoneal (IP)
injection of 206.7 mg/kg of ketamine (Bulter Schein, Middletown, PA) and 41.7 mg/kg
of xylazine. Tracheotomy was performed by inserting a 20 gauge blunt end cannula
(Ellsworth Adhesives, Germantown, WI) into the trachea and tied to ensure there were no
leaks. Following cannulation, mice were paralyzed with an intraperitoneal injection of 0.5
mg decamethonium bromide (Sigma). Mice were ventilated with a Flexivent small
animal ventilator at a frequency of 2 breaths per second and a tidal volume of 2 x 10-7 m3
and positive end-expiratory pressure of 3 cm H2O. Measurements were started once
breathing was completely by mechanical ventilation. Following measurement of baseline
lung function, mice were exposed to a PBS aerosol followed by aerosols containing
increased doses (10, 25, 50 mg/ml) of Acetyl-β-methylcholine chloride (Methacholine)
(Sigma) when C57/B6 mice were used or (2.5, 5, 10 mg/ml) when BALB/C mice were
used. Aerosols were generated by the means of an ultrasonic nebulizer and were
delivered to the inspiratory line of the Flexivent. Each aerosol was delivered for 10 sec
and measurements were made over 3 minute intervals following each aerosol. The total
lung airway resistance was recorded as the maximum resistance after each methacholine
exposure. Additionally Newtonian resistance (Rn), tissue damping (G) and tissue
elastance (H) were all measured at a dose of baseline (PBS) and 50 mg/ml of
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methacholine by averaging the three highest values at each point and is expressed as the
change from baseline for each value.
Following the Flexivent analysis, bronchoalveolar lavage fluid (BALF) was
collected by lavaging the lungs with 1 ml PBS (1% BSA in PBS) using the same cannula
associated with the Flexivent. The BALF was centrifuged and supernatant fluids were
saved for further analysis. Pelleted cells were resuspended in 100 µl PBS, counted,
cytospun onto slides and stained with Diff-Quik (Siemens Healthcare Diagnostics,
Deerfield, IL). Percentages were determined by counting of at least 100 leukocyte cells
per cytospin.
In addition, cardiac puncture was performed to collect serum for total IgE, OVAspecific IgE and OVA-specific IgG1 measurements. The heart was then perfused with 10
ml of PBS to flush the lungs of blood. The right lope of the lungs was removed for
mRNA analysis. Finally the rest of the lungs and heart were removed and fixed in 10%
formalin (Fisher) and stored at 4°C until paraffin sections were prepared by the Anatomic
pathology research service at VCU. 5 µm sections were then prepared and stained with
hemotoxin and eosin (H&E). A Nikon eclipse with a SPOT Flex Shifting Pixel Color
Mosaic (Diagnostic Instrumental inc., Sterling Heights, MI) camera was used to take
pictures of the sections.
Experimental asthma was also induced using a second IgE dependent model
(Figure 5), which also has been previously described (99), and work independent of mast
cells (as when induced in W/Wsh there was no reduction in eosinophils (work performed
by Dr. Jill Ford, shown in Figure 14)) and will be referred to as model B. In this model
the mice are initially bled and serum collected to establish baseline IgE levels. Then on
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day 0 and 14 mice were injected with 500 µg of OVA emulsified in 3 mg Alum. Alum
has been shown to make mouse experimental asthma models mast cell independent (96).
Mice were then challenged on days 19, 22, and 27 for 30 minutes with aerosolized 1%
OVA in PBS using an ultrasonic nebulizer (Medline Industries, Munderlein, IL). Finally
on day 29, Airway hyperresponsiveness (AHR) was assessed and BALF and lungs were
collected as described above.
Finally experimental asthma was induced in the mice using an IgE/mast cell
independent model, Figure 4b and referred to as model C. This model was developed by
the VCU pulmonary medicine division and its independence of IgE and mast cells were
shown using IgE-/- and W/Wsh mice (work performed by Dr. Jill Ford, shown in Figure
14). Mice again were bled on day 0 and baseline IgE was determined. The mice were
then sensitized by the injection of 100 µg of OVA emulsified in 2 mg Alum on days 1
and 8. Mice were then challenged for 45 minutes with 1% OVA aerosolized in PBS
using the same ultrasonic nebulizer described above on days 14 – 20. On day 21, AHR
was assessed and BALF and lungs were collected as described above.
III. In vivo ADAM10 inhibitor asthma studies
As a follow up to the studies with CD23Tg and ADAM10-/- studies, we also used
two hydroxamate inhibitors that are very selective for ADAM10 (see discussion under
reagents). The inhibitors have limited solubility in water and thus were dissolved in
DMSO, at a stock concentration of 20 mg/ml. This mixture was then diluted 1:20 in PBS
and 20 µg inhibitor was delivered intranasally, every three days (Figure 6 and 7), using
both the IgE/mast cell dependent and IgE/mast cell independent models. Then similar
parameters were assessed as explained above.
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Figure 6: Inhibitor dosing IgE dependent model. Model used in Figures 22-23 to show
that ADAM10 inhibitors could also block induction of asthma, similar to ADAM10-/-.
Mice were injected IP with OVA alone on days 1, 3, 5, 7, 9, 11 and 13. Then on days 40,
43 and 46 mice were challenged with OVA IN. To inhibit ADAM10 inhibitors were
given every three days IN starting on day 1 throughout the entire experiment.
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Figure 7: Inhibitor dosing IgE independent model. Model as explained in Figure 4b
used to determine, if inhibiting ADAM10 activity had any effect on IgE independent
asthma induction. ADAM10 was inhibited by administering inhibitors of ADAM10
everyday starting on day 1 throughout the entire experiment.
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Day 21

IV. ELISAs/multiplex
Total mouse IgE was measured as previously described (15). For OVA specific
IgE, R1E4 (rat anti-mouse IgE) was used as the capture antibody and OVA-DNP-Biotin
in combination with Streptavidin-alkaline phosphatase (AP) was used for detection.
Mouse IgE anti-DNP was used as a standard. For OVA-specific IgG1, OVA was used to
capture the antibody. Samples and standard (serum from a mouse hyper immunized with
OVA was used as an internal control) were detected with an AP-goat anti mouse IgG1.
Cytokines in the BALF were measured using multiplex kits from Biorad (Hercules, CA)
according to the manufacturer’s instructions. The liver enzymes aspartate
aminotransferase (AST) and alanine aminotransferase (ALT) were measured as
previously described (100).
V. qRT-PCR/RT-PCR
Total RNA was extracted from disrupted lung tissue and purified as explained
previously (50). Real time quantitative PCR (qRT-PCR) was performed using the
SsoFast EvaGreen Supermix (Bio-rad) and the MyQ2 (BioRad). For analysis the
following primers were used: GATA3, sense 5’ ACCACGGGAGCCAGGTATG-3’,
antisense 5’ CGGAGGGTAAACGGACAGAG–3’(101); T bet - sense 5’
TCCCATTCCT GTCCTTCA-3’, antisense 5’ GCTGCCTTCTGCCTTTC-3’(101); IL-25
sense 5’- GGCATTTCTACTCAGGAACGGA -3’, antisense 5’-GGTGGAGAA
AGTGCCTGT GC-3’ (102); and IL-33 sense 5’-CAGGCCTTCTTCGTCCTTCAC-3’
antisense 5’- TCT CCTCCACTAGAGCCAG CTG-3’ (102). PCR products were
amplified according to manufacture instructions with 18S as an internal control and
analyzed with iQ5 real time PCR software (version 2.0). Human ADAM10 levels were
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determined using the Taqman system using primers and probes purchased from Applied
bioscience (Carlsbad, CA) (Hs02935708_cn), and 18S was again used as an internal
control. For RT-PCR human ADAM10 (sense – CATTACACCAAAAACACCA
GCGTG, anti-sense – TCCACAC CAAATTTGGGAAACGG) and G3PDH (Readymade primers®) were purchased from Integrated DNA Technologies (Coralville, IA).
PCR was run using AccessQuickTM RT-PCR system (Promega Madison, WI).
VI. Cell culture.
293T cells were a gift from Dan McVicar (National Cancer Institute (Frederick,
MD)), and were grown in complete DMEM (10% FBS (Gemini), 100 U/ml penicillin and
streptomycin, and 2 mM L-glutamine (all from HyClone, Logan, UT). They were
transiently transfected using Fugene 6 with mouse a plasmid under the CMV promoter
expressing CD23-YFP (40) to study the effects of CD23 stability on internalization and
localization. The 293 variant (293-F) was purchased from Invitrogen (Carlsbad, CA) and
grown and transiently transfected with mouse ADAM10-HA contained in pCDNA3.1
according to the manufacturer’s protocol. Mouse CD23+-CHO (mCD23+-CHO) cells,
were previously described and grown in DMEM-GS (90) and were used to examine
internalization of mouse CD23 as well as exosome formation. RPMI 8866 cells were
maintained as described (49). Mouse B cells were isolated by sorting with anti-B220 and
stimulated with 10 µg/ml LPS (sigma) and 25 ng/ml IL-4. ADAM10 null Mouse
Embryonic Fibroblast (MEF) were a gift from Carl Blobel (Cornell University) (49).
These cells were previously selected for stable expression of mouse CD23 with
blasticidin (ADAM10-/- require 3 μg/ml, ADAM10+/- 5 μg/ml).
VII. Fluorescence Imaging
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mCD23+-CHO cells were plated at a concentration of 2 x 105 cells/ml on glass
cover slips previously coated with 0.1 mg/ml poly Lysine (sigma) and allowed to bind.
FITC-B3B4 was then added at 4°C and after 30 minutes internalization was initiated by
transferring the cells to 37°C for the time indicated. Cells were then fixed with FCM
fixation buffer (Santa Cruz Biotechnology) and adhered to microscope slides using
Prolong Gold Antifade Reagent (Invitrogen). Imaging was performed under oil
immersion at 100X on a Zeiss AxioObserver.Z1 with an integrated MRm Camera and
analyzed with Axiovision 4.63 software (Carl Zeiss, Inc. Thornwood, NY). 293T
transiently transfected with mouse CD23-YFP were also plated on poly Lysine coated
coverslips. After 24 hr the following antibodies were added 19G5 (destabilizing), 2H10
(anti-lectin, stabilizing), IgE, or IgG control and after additional 24 hr incubation, cells
were then fixed and imaged and the percentage of cells with internalization was
determined by looking at orthogonal views. In addition some cells were also stained with
antibodies against specific intracellular compartments, with antibodies against the
following antigens: EEA-1 for early endosomes (103), LAMP-1 (104) for lysosomes,
Rab11 (105) for recycling endsomes/MVB and calnexin for ER (106). The percentage of
cells with co-localization was determined, with a cell being counted as positive if any colocalization in the cell was determined.
VIII. Mouse sCD23 Release Studies
mCD23+-CHO were plated at 1 x 106/ml in six well plates and allowed to adhere.
After incubation for 30 minutes with 10 mM NH4Cl the cells were incubated with either
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Figure 8: Recombinant mutant CD23 fragments used in binding studies. Adapted
from (41), used to determine the region of CD23 important for interaction with
ADAM10.
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Figure 9: Conformation of 293-F transfection with ADAM10-HA. As a source for
ADAM10 protein, 293-F were transfected with PCDNA3.1-ADAM10-HA and
expression was confirmed by (A) western blot (anti-HA) and (B) FACS.
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19G5 or IgE for 8 hrs. sCD23 in the supernatants was determined by ELISA (40) with
2H10 (rat anti-mouse CD23 antibody) as the coating antibody and rabbit anti-mouse
CD23 for detections. EC-mCD23 (recombinant extracellular mouse CD23) was prepared in our laboratory and used as a standard.
IX. Dot/Western Blots
lz-mCD23 (showed in Figure 8 (41)) starting at 20 μg/200 μl of PBS was serially
diluted 1:2 across a Hybrid-Dot Manifold (Life Technologies, Gaithersburg, MD)
containing nitrocellulose (Pall Corporation, Pensacola, FL) and excess liquid was
removed by applying vacuum. The nitrocellulose containing CD23 was then removed
from the apparatus and blocked in 5% milk in 1X HBS and 0.05% Tween-20. Some
blots were then incubated with 19G5, IgE or nothing. Following washing, cell lysate
from 293-F cells that had been transiently transfected with HA-ADAM10 (transfection
was confirmed by Flow Cytometry and western blot (Figure 9)) expression vector two
days previously were added and blots were incubated over night at 4°C. ADAM10
binding was then detected using a rabbit anti-ADAM10 and a HRP-goat anti-Rabbit.
For mouse and human CD23 dot and western blots, CD23 was detected with either a
rabbit anti-human or rabbit anti-mouse CD23 followed by a HRP-goat anti-Rabbit. For
ADAM10 and MHC class II blots, the respective proteins were detected using Rabbit
anti-ADAM10 and Anti-H2-I/Adβ followed by their respective HRP conjugated
secondary antibodies.
X. Immunoprecipitation/Biotinylation
Human CD23 contained in supernatant or exosomes was precipitated with either
IDEC-152 in combination with Protein A/G or avidin-agarose and analyzed by western
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blot. For biotinylation experiments, RPMI 8866 cell surface proteins were biotinylated as
described by the manufacturer (Pierce). Briefly cells were suspended in 1X Hepes
Buffered Saline (HBS) containing 50 µg/ml NHS-biotin for 30 minutes at 4°C and then
washed three times in 1X Tris Buffered Saline (TBS) to remove unbound biotin. Cells
were then grown for 24 hours and exosomes were isolated as described below.
Exosomes were lysed for 10 minutes on ice in 1X HBS containing 0.5% NP-40 and a
complete protease inhibitor cocktail tablet (Roche). Biotinylated proteins were then
isolated with avidin-agarose and analyzed for CD23 by western blot. For mouse CD23
precipitation, 2H10-affi-gel (BioRad) was used, 2H10 was coupled to Affi-gel according
to manufacturer’s instructions.
XI. Isolation of Exosomes
Exosomes were isolated as previously described (79). The cell sources included
RPMI 8866 or mCD23+-CHO cultured overnight or primary mouse B cells cultured for 3
days with IL-4 and LPS. Briefly cells were pelleted by spinning them at 350 x g for 5
minutes and supernatants were harvested. To remove any possible apoptotic bodies the
supernatants were spun at 27,000 x g for 20 minutes. Finally exosomes were harvested
by spinning at 1 x 105 x g for 1 hour; the exosome pellet was resuspended in 5 mls of
PBS and pelleted again using ultracentrifugation. Some samples were then suspended in
HBS and layered over a discontinuous sucrose gradient using the following
concentrations 2, 1.3, 1.16, 0.8, 0.5 and 0.25 M sucrose in HBS at 1 x 105 x g for 17
hours. 1 ml fractions were then removed starting at the top and diluted in 4 mls of HBS.
Fractions were then by spun at 1 x 105 x g for 1 hour to pellet vesicles. Pelleted
exosomes were then suspended in equal volume of PBS with SDS and reducing agent and
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boiled; the presence of CD23 and ADAM10 were then detected via western blot as
described above.
XII. Surface Plasmon Resonance (SPR)
The association of mouse CD23 with rADAM10 was measured by SPR using a Biacore
T100 optical biosensor (GE Healthcare, Uppsala, Sweden). Lane one of a CM5 sensor
chip (Series S CM5; GE Healthcare) was activated, then blocked with ethanolamine; in
the second lane, rADAM10 (10 μg/ml diluted in 0.01M acetate, pH 4.5) was immobilized
to an equivalent of 1500 resonance units (RU) and then blocked with ethanolamine.
Recombinant lz-CD23 (amino acids, 139-331 (90) (Figure 8)) at a flow rate of 30 µl/min
was passed over the wells at a concentration of 5-100 µg/ml diluted in either (10 mM
Hepes buffered saline, ph 7.4 containing 2 mM CaCl, 1 µl/(100 µl buffer) DMSO (we
found it lower the background binding) and 0.05% (v/v) surfactant-P20 or 50 mM MES
buffered saline, ph 5.8 containing 2 mM CaCl, 1 µl/(100 µl buffer) DMSO and 0.05%
(v/v) surfactant-P20) and binding was recorded. The response from the control lane was
subtracted and affinity and Rmax was determined using the biacore evaluation software
v1.1 using steady state analysis as well as conformation change analysis. To determine
the amount of recombinant CD23 that renatured correctly, binding to IgE-affi-gel was
determined as described previously (41) The purified recombinant lz-CD23 protein
concentration was adjusted by this percentage. Finally to confirm conformation change of
the proteins a linked reaction test was run, as explained previously (107). Briefly the
same concentration of lz-CD23 (50 mg/ml) dissolved in the ph 5.8 buffer was flowed (10
µl/min) over the top of rADAM10 bound chip for different periods of time (175, 500,
750, 1000, 1500 seconds) the off rates of the curves were then compared.
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XIII. in vivo exosome studies
1 mg of 19G5 (rat IgG2a anti mouse CD23 stalk) or isotype control were injected
i.p. into BALB/C mice on days 1 and 3 as previously explained by (87). Then on day 5
mice were cardiac punctured and exosomes were isolated as explained above. In addition
in the exosome free fraction, CD23 was immunoprecipitated as explained above and the
location of CD23 was determined by western blot.
XIV. Promoter Studies
We received the human ADAM10 promoter construct in pGL3 as a gift from Dr.
Claudia Prizen (Institut fur Biochemie, Mainz, Germany) (108) (Figure 10). In initial
experiments, RPMI 8866 cells were transfected with both the ADAM10 promoter
plasmid plus 10 µg of pGL4.75 (Promega, Madison, WI) which contains the Renilla
luciferase gene under the control of the CMV promoter using the Amaxa Nucleofactor I
Solution V program X05 (Walkersville, MD). 24 hours later promoter activity was
measured at baseline and with the addition of cytokines in a 96 well format using the
Topcount Plate Counter (Perkin Elmer, Waltham, MA) using dual-glo (Promega). The
following cytokines and or antibodies were tested for their effect on ADAM10 promoter
activity; IL-4 (10 ng/ml), IL-13 (10 ng/ml), IL-21 (25 ng/ml), and anti-CD40 (1 μg/ml).
The Bay inhibitor (Bay 11-7082) was a kind gift from Dr. Steven Grant (VCU). It
specifically inhibits IκB phosphorylation and was used at a concentration of 1 μM.
XV. Creation of stable cell line
To create a stable cell line expressing the ADAM10 promoter controlling the
firefly luciferase gene, the ADAM10 promoter and luciferase gene contained in pGL3
were moved to pCDNA3, a vector that contains a neomycin cassette. PGL3 was digested
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Figure 10: Plasmids used in promoter studies. (A) Original plasmid used in ADAM10
promoter studies. (B) Plasmid used to create stably expressing cell lines for promoter
studies. The plasmid was created by moving the ADAM10 promoter and Luciferase gene
from pGL3 to pCDNA3 as explained in the material and methods. It was then (C)
linearized and RPMI 8866 cells were transfected and stably expression was selected for
with G418.
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with Pvu1 and BamH1 and pCDNA3 was digested with Nru1 and BamH1. The
fragments were then separated on a 1% TAE agarose gel and the correct size fragments
isolated using a geneclean kit (MP Biomedicals, Solon, OH) and ligated using T4 ligase
(New England Bio) (shown in Figure 10). INVaF’ chemically competent E. coli were
then transformed with the this plasmid and grown up for isolation of the plasmid (correct
ligation was tested for by sequencing). Pre-testing RPMI 8866 indentified sensitivity at
400 μg/ml G418 and Jijoye required 700 μg/ml. RPMI 8866 were then transfected with
linearized (Figure 10) ADAM10-luc-pCDNA3 and after 24 hours selection for stable
lines was begun by adding G418. Three days later cells were plated at 1 cell per well in
96 well plates to select individual clones. The clones were then further tested for
luciferase expression using Steady-glo (Promega). The results for two lines are shown in
Figure 42. The luciferase activity in subsequent studies was normalized to total protein as
measured using Bradford assay, and all data shown was generated using this cell line.
XVI. FACS analysis
It was necessary to determine if the 293-F cells used in the interaction studies
above were indeed overexpressing ADAM10. 24 hours after transfection 1 x 105 cells
were stained with FITC anti-mouse ADAM10 (R&D) and expression was determined
using a Coulter FC500 Flow Cytometer and the data was analyzed using the CXP
software (Beckman Coulter Fullerton, CA) and compared to untransfected cells.
To test if cytokines as well as activation had an effect on ADAM10 protein levels, flow
cytometry was used. 1 x 105 RPMI 8866 in 100 μl were blocked with Fc block (Miltenyi,
Bergisch Gladbach, Germany) for 15 minutes and then stained with FITC-anti-human
ADAM10 (R&D) for 30 minutes at 4°C, and then washed. The cells were then examined
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as explained above. Before testing RPMI 8866 were activated with 1 μg/ml of antiCD40,10 ng/ml IL-4, 25 ng/ml IL-21 or media alone for 24 hours and then tested for
ADAM10 levels.
For carboxyfluorescein diacetate succinimidyl ester (CFSE) (molecular probes,
Eugene, OR), 5 x 106 primary human tonsillar B cells were stained according to
manufacturer’s recommendations and then one aliquot was analyzed to establish a
baseline while the others were cultured with anti-CD40 (1 μg/ml), IL-4 (10 ng/ml) and
IL-21 (200 ng/ml) as explained previously (109). After 5 days in culture, cells were then
harvested and analyzed using a BD Canto and analyzed using FCS express software V3.
XVII. in vitro ADAM10 inhibitor studies
Primary B cells were isolated and stimulated as previously described (15).
Briefly, tonsils were obtained by routine tonsillectomies and obtained through the Tissue
and Data Acquisition and Analysis Core here at VCU. The tonsils were then disrupted
using a Seward Stomacher 80 Biomaster Lab Blender (Brinkmann, Westbury, NY) and a
single cell suspension was obtained. Cells were then positive selected using anti-IgD in
combination with magnetic beads (Miltenyi). B cells were then plated at 12,500 cells/well
in 200 µl of CRPMI (RPMI 1640 containing 10% FBS (Gemini), 100 U/ml penicillin and
streptomycin, 1 mM Sodium pyruvate, 10 mM HEPES, 100 mM non-essential amino
acids and 2 mM L-glutamine (all from HyClone, Logan, UT) as well as 50 µM 2mercaptoethanol (Invitrogen, Carlsbad, CA)) plus 10 ng/ml IL-4 (R&D), 1 µg/ml antiCD40 and 200 ng/ml IL21 and grown at 37°C and 6% CO2. To determine, the role of
ADAM10 in immunoglobulin synthesis, cultures were also treated with either the
ADAM10 inhibitor from Glaxo (1.25 μM) or Incyte (INC008765) (10 μM), or with the
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carrier (DMSO) as a control. For sCD23, supernatants were isolated after 5 days and for
immunoglobulin after 14 days and levels were determined by ELISA as explained below.
To determine if the decreased IgE production by the addition of the ADAM10 inhibitor
was because of decreased sCD23 it was added back at 2 µg/ml (sCD23 was purified from
RPMI 8866 cultures supernatants using IDEC-152 coupled to affi-gel 10 in the presence
of 2 µM calcium. sCD23 was then released by the addition of 10 mM EDTA, the
concentration was then determined by ELISA and frozen in the -70°C until used). In
addition to primary tonsillar B cell cultured, ADAM10 inhibitors were also added to
PBMC cultures. PBMC were obtained by from whole blood by Ficoll (BD) density
gradient centrifugation and cultured at 300,000 cells/well in CRPMI containing IL-4, IL21 and anti-CD40 as explained above. All studies were performed in accordance with the
Virginia Commonwealth University Institution Review Board.
XVIII. Human Elisa/Elispot
Human IgE, total IgG and total IgM as well as sCD23 were described previously
(109).
Human IgE elispots were performed following the basic outline explained in
(110) that was adapted to use for IgE. Briefly, tonsillar B cells were isolated and plated
(12,000 cells/well) as explained above. Then on day 8 cells were isolated and washed
and replated in complete RPMI containing IL-4, IL-21 and anti-CD40 in MultiScreen
Filter plates (Millipore, Billerica, MA) pre-coated with mouse anti-human IgE (4.15) (5
µg/ml). Twenty hours later plates were washed and IgE was detected using biotinulatedmouse anti-human IgE (Southern Biotech (clone B3102E8) (1:25,000).
XIX. Proliferation
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To determine ADAM10 inhibition effect on proliferation, primary B cells,
isolated as explained above, were plated at 100,000 cells per well in 200 µl of CRPMI
containing IL-4, IL-21 and anti-CD40. After 96 hours of growth, cells were pulsed with
1 µCi/well of [H3]-thymidine (Perkin Elmer) for 24 hrs. Thymidine incorporation was
then determined by harvesting the plates using a filtermate cell harvester onto GFC
plates. Plates were then dried for at least two hours. 25 µl of scintillation fluid was then
added and counts were determined using the Topcount Plate Counter (Perkin Elmer,
Waltham, MA).
For the siRNA studies, RPMI 8866 were plated at 50,000 cells/well after sorting
and immediately pulsed with 1 µCi/well of [H3]-thymidine for 24 hrs. Plates were then
harvested and read as explained above.
XX. ADAM10 siRNA
ADAM10 involvement in proliferation of B cells was tested by transfecting RPMI
with a GFP expressing plasmid and pSuper (Oligoengine, Seattle, WA) (a gift from Dr.
Carl Blobel at Cornell University (Figure 11)) expressing siRNA for human ADAM10
(sequence GACATTTCAACCTACGAATttcaagagaATTCGTAGGTTGAAATGTC)
using the Amaxa kit explained above, the lower case letters are the 9 non-complementary
spacer. 24 hours later the cells were sorted for GFP expression using the MoFlo cell
sorter (Beckman Coulter) and replated as explained under proliferation. Knockdown of
ADAM10 was also examined by RT-PCR as explained above.
XXI. Creation of stable siRNA expressing line
To create a stable knockdown cell line of ADAM10, siRNA for human ADAM10
was moved from pSuper to pSuperior (Oligioengine) as pSuperior contains a Neo cassette
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and its expression is run under a tetO system. The tet is expressed by pCDNA6/TR and
is turned on by the addition of doxycycline (plasmids shown in Figure 12). The siRNA
portion of pSuper was moved by amplifying it via PCR and ligated into pCR2.1 using TA
cloning kit (Invitrogen) and finally cloned into pSuperior. Stable expression of
pCDNA6/TR is selected for with the addition of blasticidin (Invitrogen) and RPMI 8866
were found to die at 4 μg/ml or more. pCDNA6/TR was first linearized and then
transfected into RPMI 8866 cells. After selection siRNA-ADAM10 pSuperior was
linearized and transfected into the pCDNA6/TR RPMI 8866 cells and selected for with
G418. siRNA was then induced by the addition of doxycycline.
XXII. Statistical analysis
All statistics were done using the student two-tailed T-test. When multiple
comparisons were performed Bonferroni correction was also used. All error bars
represent standard deviation or standard error (indicated in the Figure legend). Lines in
graphs show groups that were compared.
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Figure 11: pBasic with ADAM10 siRNA. Plasmid co-transfected, with GFP expressing
plasmid, into RPMI 8866. RPMI 8866 were transfected to study ADAM10 role in B cell
proliferation.
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Figure 12: Plasmids used to make stable expressing ADAM10 siRNA. siRNA was
moved from pSuper shown in Figure 12 to pSuperior by PCR as explained in the material
and methods. RPMI 8866 were then transfected first with plasmid in (A). Cells were then
selected for resistance to blasticidin. After selection of a single colony, these cells were
transfected with the linearized plasmid shown in (B) and selected for G418 resistance.
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Results
I. ADAM10 activity increases asthma induction in IgE dependent models of
experimental asthma, but not IgE independent.
A. ADAM10-/- and CD23Tg mice have decreased signs of allergic lung inflammation
in an IgE dependent model. To test the importance of CD23 and ADAM10 in asthma
induction we used the murine models of allergic lung inflammation shown in Figure 4
and 5. In agreement with Haczku et al. (53), we found that CD23Tg mice (BALB/C
background), which have suppressed IgE ((56) and Figure 14b) and have high expression
of CD23 on lymphocytes, exhibited decreased eosinophilia compared to LM controls
(Figure 14a) when tested in an IgE-dependent asthma model (model A). We also
observed decreased levels of the chemokine IL-5 (Figure 14c) which may explain the
decreased eosinophilia seen. In contrast to the IgE-dependent model (model A) no
differences between CD23Tg and LM controls in BALF eosinophilia was seen when
model C was used (Figure 13a, performed by Dr. Jill Ford). In addition, when the
CD23Tg mice were crossed onto an IgE-/- background and Model B was used (Figure
13c), there was no further reduction in eosinophils in the BALF. These data indicate that
the decrease in asthma severity observed in the CD23Tg occurs primarily because of the
decreased IgE in these animals. Given that ADAM10 is the CD23 sheddase and that
mice which lack B cell ADAM10 have greatly increased CD23 expression (50), we next
tested whether these mice would also have reduced inflammation with model A. Lung
AHR in ADAM10-/- mice (C57BL/6 background), as determined by total lung resistance
(RL) (Figure 15a) and forced oscillation technique (Figure 15b) was significantly lower
than in the LM sensitized control mice. Figure 16c shows that the ADAM10-/- mice also
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Figure 13: Model B is IgE/mast cell independent, Model C is IgE dependent mast
cell independent. This work was performed by Dr. Jill Ford and Sarah Norton. To
determine if these models were dependent on mast cells or IgE, the BALF eosinophilia
was determined after the respective models were induced in IgE-/-, W/Wsh or wild type
(WT) mice. (A) Model C was induced and equal amounts of eosinophils in the BALF
were found in the IgE-/- and (B) W/Wsh and their respective controls. This shows that this
model is independent of both IgE and mast cells. n = 9 (C) When model B was induced in
IgE-/- and WT there were significantly less eosinophils in the IgE-/- mice compared to
their LM controls. (D) However, when WT and W/Wsh eosinophilia were compared after
induction of model B equal percentage of eosinophils were found in both mice. n = 8.
This shows that for model B it is dependent on IgE, but not on mast cells. A and C
additionally, show that the CD23Tg are compared to WT mice after induction of these
two models, they are only able to control models that are dependent on IgE.
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Figure 14. Overexpression of CD23 in CD23Tg can control eosinophilia in an IgE
dependent model (A) Asthma was induced in BALB/C LM and CD23Tg mice using
model A. BALF was collected and the percentages of cells were determined, as indicated
in the Materials and methods, by counting at least 100 cells. Shown is the average of four
mice. (B) Serum total IgE was measured by ELISA, shown is the average of 4 mice per
group. (C) The cytokines in the BALF of the mice used in A were determined using
multiplex kits according to the manufactures’ instructions, shown is the average of 4 mice
per group. * = P value <.05 and ** = P value <.01. Error bars represent standard error.
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Figure 15 – Conditional removal of ADAM10 decreases the severity of disease in a
IgE/mast cell dependent model (A) Mice were sensitized and challenged using model A
(mice are on a C57BL/6 background). On day 29 lung function was assessed by
measuring total lung resistance as explained in the Material and Methods; shown is the
average of at least 4 mice per treated group. Significance is between ADAM10-/- (called
A10-/- in figure) and LM. (B) Rn, Tissue Dampening and Elastance were determined at
baseline (PBS) and after the addition of 50 mg/ml of methacholine, with the average of
the three maximum points at each dose being used for each mouse. Shown is the average
of at least 4 mice per group. (C) Cells from the BALF were counted and stained as
explained in the Materials and methods. Percentages of cells were then determined in the
BALF by counting of at least one hundred cells and numbers presented is the average of
at least four mice. (D) The levels of OVA specific IgE in the serum were determined by
ELISA, shown is the average of at least five animals. (E) Cytokine levels in the BALF
were determined by multiplex analysis, shown is the average of at least four animals
(same key as in C). * = P value <.05, ** = P value <.01 and *** = P value < .001. Error
bars represent standard error.

62

63

had significantly reduced eosinophilia in the BALF compared to LM sensitized controls.
Percentages of other cell types in the ADAM10-/- mice closely resembled the unsensitized
animals. ADAM10-/- mice also had reduced serum antigen-specific IgE levels (Figure
15e). In addition, although the mRNA levels for GATA3 and Tbet were not changed
compared to LM (Figure 15d) there was a significant decreases in both Th1 and Th2
cytokines (Figure 15f). To determine if the ADAM10-/- had decreased tissue
inflammation as well, lungs were sectioned and stained with H&E as explained in the
Materials and methods. As shown in Figure 16, the ADAM-/- also had decreased
inflammation and eosinophil infiltration. In contrast, when asthma was induced with
model C, the ADAM10-/- (Figure 17 and 18) like the CD23Tg (Figure 13a) was not
significantly different from the LM sensitized animals with respect to AHR (Figure 17a)
or BALF eosinophilia (Figure 17b, c). However, the Th1 cytokines IL-12 and MIP1-α
were still significantly decreased in the IgE independent model, when comparing the
OVA sensitized ADAM10-/- mice to LM controls (Figure 17d). Overall these data show
that increasing CD23 by inhibiting ADAM10 on B cells has the potential for strongly
inhibiting the IgE dependent, but not the IgE independent lung inflammatory response by
reducing IgE levels.
As the ADAM10-/- had decreased eosiniophilia and other signs of asthma when
model A was used, we sought next to determine if was because of decreased IgE binding
of and signaling through its high affinity receptor on mast cells or some other
mechanism. To do this model B was used which model as shown in Figure 13b and c is
dependent of IgE, but not on mast cells. Like with model A, when the ADAM10-/- mice
were compared to LM, the signs of experimental asthma were decreased (Figure 19 and
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Figure 16: ADAM10-/- mice also have less tissue eosinophilia. Lung sections from
mice used in Figure 15 were stained with H&E and shown in the large photomicrographs
are 10X and inserts are 100X. (A) ADAM10-/- and (B) LM controls. Shown is a
representative photomicrograph of at least 4 mice per group.
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Figure 17: ADAM10 can control only IgE dependent disease. Experimental asthma
was induced using Model C (IgE/mast cell independent) in ADAM10-/- (called ADAM10
KO in figure) and LM controls. (A) AHR was measured by RL. (B) Percentage of cells in
the BALF was determined, as explained in Figure 15. (C) Total number of each cell type
in the BALF was determined by multiplying the percentage by the total number of cells
in the BALF. (D) Cytokines in the BALF was determined by multiplex analysis. (E)
OVA-specific IgE found in the serum of the mice at day 29 was determined by ELISA.
Shown is the average of at least five mice per group. Error bars represent standard error.
* = P value < .05
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Figure 18: Tissue eosinophilia was normal after IgE independent asthma model
induction. Lung sections from mice used in Figure 17 were stained with H&E and shown
in the large photomicrographs are 10X and inserts are 100X. (A) ADAM10-/-and (B) LM
sensitized controls. Shown is a representative picture of at least 4 mice per group.
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Figure 19: B cell specific ADAM10-/- mice have decreased asthma signs after
induction of IgE dependent/mast cell independent model of asthma compared to LM
controls. Experimental asthma was induced using Model B (IgE dependent/mast cell
independent). (A) AHR was measured by RL as explained in Figure 15. Comparison is
between ADAM10-/-(called ADAM10 KO in figure) and LM controls. (B) Percentage of
cells in the BALF was determined, as explained in Figure 15. (C) Total number of
eosinophils in the BALF (D) OVA-specific IgG found in the serum of the mice at day 29.
Shown is the average of at least 5 per group. Error bars represent standard error. * = P
value < .05
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Figure 20: Tissue eosinophilia was also decreased. Lung sections of sensitized mice
used in Figure 19 were stained with H&E and shown in the large photomicrographs are
10X and insets are 100X. (A) ADAM10-/- and (B) LM sensitized controls. Shown is a
representative photomicrograph of at least 4 mice per group.
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19). This included AHR as shown by RL (Figure 19a) and eosiniophilia (Figure 19b) as
well as lung inflammation (Figure 20). These data additionally show that ADAM10 on B
cells is important for the exacerbation of IgE dependent disease, but this exacerbation
cannot be explained completely by the decreased IgE signaling and degranulation of mast
cells. The nature of other possible IgE dependent mechanisms will be discussed later.
B. ADAM10 inhibition blocks the induction of experimental asthma
Given the above finding that mice lacking B cell ADAM10 have minimal
pathology in IgE dependent lung inflammation, we sought to determine if inhibiting
ADAM10 activity in WT mice would have the same effect. Experiments were conducted
with two hydroxamate inhibitors of ADAM10 (both inhibitors were found to cause a
similar decrease in asthma signs, the data from both experiments was thus combined).
The inhibitors were dissolved in DMSO and administered intranasally during the
induction of the asthma model (Figure 6). The inhibitors were administered intranasally
at a concentration of 1 mg/kg (91) (based on a lung volume of 900 µl this is a
concentration of 32 µM), a dose based on previous cell based assay performed by Incyte
where ADAM10 in vivo should selectively be inhibited, in DMSO/PBS every three days
throughout the experiment. As a control, the ADAM10 inhibitors were also administered
to unsensitized mice and found to have no effect (Figure 21 b, c). Using the IgEdependent model (model A) we found that the inhibitors significantly decreased the signs
of allergic airway inflammation, while having no toxic effects as measured by weight loss
or the serum levels of liver enzymes, aspartate aminotransferase and alanine
aminotransferase (Table 1). The carrier (5% DMSO in PBS) was well tolerated;
responses of the LM controls in Figure 15c were similar to those in DMSO treated mice
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(Figure 21c). Thus, any reduction in asthma severity was due to inhibition of ADAM10
activity. We also found that similar to the ADAM10-/- mice (Figure 15), AHR as
measured by forced oscillation technique (Figure 21b), as well as RL (Figure 21a) was
decreased by the administration of the ADAM10 inhibitor. The eosinophilia in the BALF
was also found to be significantly reduced (Figure 21c). This decrease was even more
drastic than in the ADAM10-/- mice, from ~50% to 20% in the ADAM10-/- (Figure 15c)
and from ~50% to 5% (Figure 21c) in WT mice treated with the inhibitor. Thus, this
suggests that ADAM10 expression by cells, other than B cells, is important in the
progression of experimental asthma. The inhibitors may also block ADAM10 activity on
epithelial cells, because they can control the allergic response (reviewed in (111)) and
have high expression of ADAM10 (82). Although the percentage of macrophages was
increased, there were actually only a slight increase of macrophages in the BALF (Figure
21d) compared to DMSO control after inhibitor treatment. To determine if the decrease in
AHR and eosinophilia was because of an inhibition of IgE synthesis, as was the case in
the ADAM10-/- mice, we measured the levels of total IgE in the serum (Figure 21e), but
found it was unchanged from the LM. However, local production of IgE in the BALF
was significantly decreased compared to DMSO treated mice (Figure 21f). Hydroxamate
inhibitors are known to have a short half-life in serum (112), however as clearly shown
by our data when administered intranasally the inhibitory activity is sufficient for at least
a 3 day period. The effects on IgE suggest local activity, however, blocking only the
local production of IgE is advantageous as it has been shown that local but not systemic,
production of IgE (113) is important for disease progression.
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Table 1. ADAM10 inhibitors are not toxic to mice. Just prior to measurement of AHR
the mice were weighed. Shown is the average of at least 8 mice per group. The serum
isolated after sacrifice of three mice of similar treatment were pooled together and then
AST and ALT levels were measured in the serum as explained in the material and
methods. Shown is the average of at least two different pools. Error represents standard
error.
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Parameter

DMSO – OVA Sensitized

ADAM10 inh – OVA
Sensitized

Weight (time of sacrifice)

20.49 ± 0.5

20.43± 0.28

AST (aspartate
aminotransferase)

13.666 ± 6.81

15.558 ± 6.87

ALT (alanine
aminotransferase)

2.59 ± 0.93

3.64 ± 0.67
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Figure 21 – ADAM10 inhibitor potentially blocks the induction of an IgE/mast cell
dependent model through blocking the Th2 response. Asthma was induced using the
IgE-dependent model (Model A). 1 mg/kg in a 20:1 mixture of PBS/DMSO of an
ADAM10 inhibitor (called A10 inh in the Figure) was injected intranasally every three
days throughout the experiment in wild type C57BL/6. The control mice (wild type
C57BL/6) received just the PBS/DMSO mixture. (A) On day 47 AHR was measured
using total lung resistance (significance is between ADAM10 inhibitor and DMSO
treated) and (B) forced oscillation measurements as explained in Fig 15b. Data represents
the average of data from at least four sensitized mice and two unsensitized mice. (C)
Percentages of BALF cells were determined as in Fig 15c. Shown is the average of at
least three animals (same key as B). (D) Total IgE in the serum as determined by ELISA,
average of at least four animals. (E) Total IgE in the BALF as determined by ELISA,
average of at least three animals. (F) qRT-PCR of total lung RNA was performed using
the primers listed in material and methods. Shown is the average of at least five animals.
The unsensitized groups were combined, as no difference where seen between them. (G)
BALF cytokine levels as determined by multiplex ELISA. Shown is the average of at
least five animals per group. Again unsensitized groups were combined. (same key as F).
Number above comparison line equals P value, * = P value < .05 and ** = P value <.01.
Error bars represent standard error.
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Figure 22: Tissue eosinophilia is decreased by the administration of ADAM10
inhibitor. In order to determine if inhibiting ADAM10 activity similarly suppressed
tissue inflammation, lung sections of the mice used in Figure 21 were stained with H&E
and shown in the large photomicrographs are 10X and inserts are 100X. (A) ADAM10
inhibitor treated (labeled as AD10) and (B) DMSO treated mice. Shown is a
representative photomicrograph of at least seven per group.
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Figure 23: Signs of asthma are decreased when ADAM10 inhibitor is administered
during induction of IgE dependent asthma model in BALB/C. To determine if the
effects of the ADAM10 inhibitors were just because of the C57BL/6 background,
experimental asthma was induced like in figure 19 in BALB/C mice and INC009588 was
administered throughout the experiment. (A) AHR as measured by RL (comparison is
between DMSO and ADAM10 inhibitor treated) or (B) Rn, tissue damping and elastance.
(C) Percentage of cells in BALF determined as explained in Figure 15c. (D) Cytokines in
the BALF. (E) Total IgE in the BALF. (F) Expression of selected genes in the left lobe of
the lung determined as explained in figure 19. Shown is the average of at least four mice.
Error bars represent standard error. * = P value < .05
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Figure 24: Similar to ADAM10-/- mice the administration of ADAM10 inhibitor
cannot decrease asthma signs when an IgE independent model is used. With the
ADAM10-/- we found that ADAM10 on B cells was only important in IgE dependent
diseases. To determine if the same was true with inhibition of ADAM10 activity
experimental asthma was induced using the schedule shown in figure 6. (A) AHR as
measured by Rn, G (tissue damping) and H (Elastance). (B) Total cells of each type in the
BALF. This was determined by multiplying the percentages of each cell type by the total
amount of cells found in the BALF. (C) Percentages of cells in the BALF were
determined as explained in figure 16c. (D) Gene expression was determined as explained
in Figure 19. (E) Cytokines expression in the BALF was determined as explained in
Figure 15. (F) IgE levels in the BALF as determined by ELISA as explained in the
materials and methods. Shown is the average of at least six mice. Error bars represent
standard error. * = P value <.05, *** = P value < .001.
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Figure 25: ADAM10 inhibitors have no effect on tissue eosinophilia when IgE
independent model is induced. To determine if inhibition of ADAM10 activity had any
effect on lung inflammation, lung sections from the mice used in Figure 24 were stained
with H&E. Shown in the large photomicrographs are 10X and areas of obvious
inflammation as insets at 100X. (A) ADAM10 inhibitor treated and (B) DMSO treated.
Shown is a representative photomicrograph of at least 4 mice per group.
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To test if ADAM10 inhibitors have effects beyond that of inhibiting IgE, we
isolated total lung mRNA from ADAM10 inhibitor treated and control mice, and used
qRT-PCR to measure the levels of several components known to be important in asthma
progression, including the Th2 response. In the ADAM10-/- mice we found that the
decrease in the levels of serum OVA-specific IgE compared to LM correlated with a
decrease in Th2 cytokines (Figure 15f). To determine what effect administration of the
inhibitor had on T cell responses, the major T cell transcription factors mRNA levels
were measured by qRT-PCR. Analysis demonstrated GATA3 mRNA levels were
significantly decreased after ADAM10 inhibitor treatment compared to DMSO treatment,
while Tbet mRNA levels were not (Figure 21g). Recently two cytokines, IL-25 and IL33 (reviewed in (114)), have been implicated in the induction of a Th2 response. While
minimal IL-25 mRNA levels were detected, message for IL-33 was significantly
decreased in mice treated with the ADAM10 inhibitor. These results further support the
hypothesis that ADAM10 on non-B cells is important in the initiation of the Th2 response
in the lung. Interestingly, when cytokines were analyzed in the BALF, IL-13 levels were
not decreased (Figure 21h) when given the inhibitor, in spite of the known association of
IL-13 and AHR (115). Alternative sources of IL-13 production (116), not affected by
ADAM10 inhibition, could potentially explain this finding. It is also interesting to
speculate that ADAM10 inhibition decreases the ability of IL-13 (115) to act on epithelial
cells in the lung as will be discussed later. The decreased eosinophilia (Figure 21c)
observed after ADAM10 inhibition can be explained by the strong inhibition of IL-5, the
primary chemotactic factor in the recruitment of eosinophils, as well as by significant
decreases in eotaxin and KC which are also involved in eosinophil recruitment (Figure
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21h). Finally, IL-9 in the BALF was also found to be decreased by the addition of the
ADAM10 inhibitor. IL-9 is produced by both Th2 cells as well as the new subclass of T
helper cells, Th9, and is known to enhance airway inflammation (117). When lung
inflammation was investigated by H&E staining after treatment, it was also found to be
decreased in the ADAM10 inhibitor treated mice compared to DMSO (Figure 22).
Overall, the multiple changes help explain how the inhibition of ADAM10 suppresses
IgE-dependent lung inflammation.
When the ADAM10 inhibitor administration was repeated in BALB/C mice using
model A (Figure 23), similar results were seen expect the eosinophilia decrease in the
BALF was not as drastic (60% to 23% in the BALB/C compared to 50% to 5% in the
C57BL/6 after inhibitor treatment). Finally, when the ADAM10 inhibitor was
administered every three days during the induction of model C (IgE independent (Figure
7)), no effect was seen (Figure 24 and 25). Overall these results show that regardless of
the mouse background, the administration of an ADAM10 inhibitor is able to block the
induction of experimental asthma.

II. ADAM10 is also required for CD23 sorting into B cell derived exosomes.
Considering that inhibiting ADAM10 can decrease the signs of asthma, potentially due to
increased CD23 expression, we sought to further understand how ADAM10 cleaves
CD23.
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Figure 26: CD23 is internalized upon ligand binding. mCD23+-CHO (90) were plated
on poly-lysine coated coverslips and allowed to adhere. After staining with a FITC-rat
anti-mouse CD23 lectin (B3B4) antibody for 30 min at 4°C, cells were either (B)
transferred to 37°C for 30 min or (A) left at 4°C and visualized.
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Figure 27: Amount of CD23 internalized is affected by stability. To test if the stability
of CD23 affected the amount of internalization a different cell type, HEK 293T
transfected with mouse CD23-YFP were plated on coverslips and surface CD23 was
either stabilized by the addition of 2H10 (anti-lectin) or IgE or destabilized with 19G5 or
left untreated as a control. The percentage of cells where CD23 was internalized
(examples are shown in (A) CD23 is cell surface bound or (B) internalized) was
calculated after a 24 hr incubation (37°C) with the indicated antibodies. Fig 27A and B
data are representative micrographs from 3 experiments of similar design and 27C
represents data the averaged. Error bars represent standard deviation. * = P value < .05,
** = P value < .01.
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Table 2: Internalized CD23 localizes to endosome compartments. HEK 293T cells
were transiently transfected with CD23-YFP and examined for CD23 internalization after
48 hrs. Cells were then stained with antibodies against different cellular compartments
and their respective secondary antibodies. Percentage of cells with co-localization was
determined, with a cell being counted as positive if any co-localization was determined.
Data shown was the average of three independent experiments. Error represents standard
deviation.
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Table 2: CD23 localization
Marker

Compartment

Calnexin

ER

Early endosomal Ag

Endosome

LAMP1

Lysosome

Rab11

Recycling endosomes/MVB

% Co-localization with
CD23
11.7±0.71
72.1±18.5
21.2±8.8
95.1±4.4
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A. Correlation between CD23 internalization and CD23 cleavage - CD23 binding
reagents have been defined previously according to whether they decreased or increased
CD23 cleavage, these two activities were called stabilizing or destabilizing, respectively
(40). To further investigate this phenomena, we first sought to confirm studies (36;118)
that showed that anti-CD23 causes ligand internalization. mCD23+-CHO cells were
labeled with FITC-anti-CD23 (FITC-B3B4), which is an anti-lectin mAb, transferred to
37°C and internalization was followed (Figure 26b). Examination of orthogonal views
demonstrated that the visualized punctate spots were found inside the cell after 30
minutes, while at 4°C (Figure 26a) they were still at the cell surface; thus, showing that
CD23 is internalized following anti-lectin binding. To determine if there was a
correlation between CD23 cleavage and internalization, 293T cells were transfected with
CD23-YFP. Previous studies had shown that stabilizing CD23 with IgE or anti-lectin
antibodies decreased CD23 cleavage while destabilizing antibodies increased cleavage
(42;87). The CD23-YFP expressing 293T cells were then incubated with the indicated
antibodies for 24 hours and examined by immunofluorescence. The percentage of cells
with internalized CD23 was then determined and the data is summarized in Figure 27c.
Examples of cells with CD23 still at the surface and after internalization are shown in
Figure 27a and b respectively as well. We found that significant CD23 internalization
occurs naturally even in the absence of ligand, however, anti-stalk mAbs (19G5)
increased this internalization while IgE and the anti-lectin (2H10) decreased
internalization compared to this control. Of note with anti-lectin mAbs and IgE there still
is internalization as shown in Figure 27c it is just decreased as compared to control. As
the anti-lectin and IgE were also found to act similarly, only IgE was used for the
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remainder of the study. These data suggests that the stability effect on cleavage could be
related to internalization. In additional studies, co-staining with antibodies against
markers of different subcellular compartments was performed. This data is summarized
in Table 2. CD23 co-localization with EEA1 and Rab11 indicating endosomal trafficking
and is in agreement with previous work that showed CD23 traffics through the
endosomal pathway (36;118).
B. Enhanced internalization correlates with enhanced sCD23 production Previous studies have shown that subsequent to the internalization of CD23-bound
IgE/antigen complexes, some CD23 eventually recycled back to the cell surface (36).
Thus to determine if the internalized CD23 as seen in Figure 28 was related to the
fragments found in the supernatant or if it is recycled, cells were treated with antibodies
that stabilize (IgE) or destabilize (19G5) CD23 +/- NH4Cl. NH4Cl prevents the
progression of proteins in the endosomal pathway by neutralizing the endosomal pH
(119). As shown in Figure 28a, the enhanced CD23 cleavage that is characteristic of the
anti-stalk mAb, 19G5 (87), is reversed in the presence of 10 mM NH4Cl. In contrast,
NH4Cl treatment of mCD23+-CHO where CD23 was stabilized with monomeric IgE had
no affect with respect to sCD23 production (Figure 28b). Note also the amount of sCD23
released into the supernatant was significantly lower in cells where CD23 was stabilized
compared to cells where CD23 had been destabilized. NH4Cl treatment brought sCD23
release from cells in which CD23 was destabilized down to levels only 1.5 times (30
ng/ml vs 18 ng/ml) higher than that released from cells where CD23 was stabilized. In
addition, this inhibition of enhanced CD23 cleavage is similar to what was seen with an
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Figure 28: Intracellular compartments are important for the release of CD23
fragments. sCD23 ELISA of 8 hr cultures supernatant of mCD23+-CHO cells ± 10 mM
NH4Cl treatment. CD23 cleavage was induced by the addition of a destabilizing antibody,
19G5 (A) or inhibited by the addition of IgE (B). (C) Using RPMI 8866, CD23 was
destabilized with the addition of 11E10 (rat anti-human CD23 stalk antibody) +/Chloroquine. sCD23 in the supernatant was then measured by ELISA. (D) Purified IgD+
tonsilor B cells were stimulated with IL-4, IL-21 and anti-CD40 for 8 hrs +/- NH4Cl.
sCD23 in the supernatant was then measured by ELISA. Error bars represent standard
deviation. * = P value <. 05

99

A.

B.
40

300

P value < .005

NS

sCD23 (ng/ml)

sCD23 (ng/ml)

30
200

100

20

10

0

0

19G5

IgE

19G5 + NH4Cl

IgE + NH4Cl

D.

C.
CD23 is cleaved intracellular in 8866 as well

sCD23 release after 8 hrs. from stimulated primary B-cells
400
Media alone
Media plus NH4CL

P value = 0.0188

*

600

300

ng/ml sCD23

ng/ml sCD23

*

400

200

200

100

0

0
Normal

Chloroquine

Normal + 11E10

Chloroquine + 11E10

T1

T2

* = P value > .01

100

Figure 29: ADAM10 and CD23 interact inside the cell. (A) ADAM10-HA and CD23
doubly transfected HEK 293T cells were grown on coverslips and incubated with rabbit
anti-HA (Red) and rat anti-mouse CD23 (Green); after washing detection was with PEanti-rabbit IgG and FITC anti-rat IgG. (B) CD23 stably transfected MEFs derived from
ADAM10-/- embryos (completely knockouts) (14) were stained with FITC-B3B4 and
either left at 4°C or transferred to 37°C and examined after 30 min. Each of the above
pictures is a representative of at least two independent experiments. (C) CH23+-CHO
cells were stained with an FITC-B3B4 and maintained at 4ºC. In B and C internalization
was allowed for 45 minutes at 37 ºC. (D) Preincubated with 10 mM NH4Cl for 30
minutes before staining and maintained in 10 mM NH4Cl when transferred back to 37ºC.
(E) Cells transferred to 37°C but not incubated with NH4Cl. Pictures are a representative
of three independent experiments. (F) The average number of cells under each condition
that had internalized CD23 after 45 minutes. Shown is the average of at least 3 different
experiments. Error bars represent standard deviation. ** = P value < .01
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ADAM10 inhibitor (49). A similar trend was also seen in both primary human B cells
and RPMI 8866 (Figure 28c and d) in which NH4Cl caused a 50% drop in sCD23 similar
to what was previously found with inhibition of ADAM10 (49). Thus, when
internalization was inhibited, as seen with IgE in Figure 28c, the NH4Cl effect is minimal
and the converse is true when internalization is enhanced. To ensure that NH4Cl was not
simply blocking internalization, mCD23+-CHO cells were stained with FITC-anti-CD23
in the presence or absence of NH4Cl and then internalization was allowed (Figure 29c-e).
This shows that NH4Cl does not block ligand induced internalization and that the effect
of NH4Cl is related to neutralization of the intracellular compartments.
As stated in the introduction, the primary site of CD23 cleavage was thought to be
the cell surface. Conversely, our data indicates that a majority of CD23 is internalized
before it is released from the cell (Figure 27c). To determine where CD23/ADAM10 colocalization occurred, 293T cells were doubly transfected with ADAM10-HA and CD23.
After 24 hrs the cells were co-stained for CD23 and ADAM10 (Figure 29a). CD23 was
evident both on the cell surface and inside the cell. In contrast, ADAM10 was mostly
intracellular, consistent with other reports (70). Co-localization was also primarily
intracellular. This led us to hypothesis that ADAM10 has no role in the internalization of
CD23. To confirm our hypothesis that CD23 internalization did not require ADAM10,
CD23+-ADAM10-/--MEFs were cultured with FITC-B3B4 as in Figure 27a and b and
clear internalization was seen when bound by anti-CD23 (Figure 29b). Overall this
figure shows that NH4Cl blocks intracellular ADAM10 and CD23s interaction,
suggesting that low pH might affect their interaction.
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Figure 30: Full length CD23 was found in B cell secreted exosomes. Exosomes were
isolated by ultracentrifugation as explained in the material and methods from overnight
cultures of RPMI 8866 cells, a human B-cell line. (A) Exosomes were then overlaid onto
a gradient of 2, 1.3, 1.16, 0.8, 0.5 and 0.25 M sucrose and spun overnight at 1 x 105 x g.
One ml fractions were collected and added to four ml HBS and again spun for one hour at
1 x 105 x g. Pelleted samples were then analyzed by western blot with Rabbit anti-CD23.
(B) The blot was stripped and also analyzed for ADAM10 with Rabbit anti-ADAM10.
(C) To confirm that CD23 in exosomes was full length, cell lysate from RPMI 8866 were
compared to CD23 from exosomes. (D) Exosomes from mouse CD23+-CHO cells where
CD23 had been destabilized with 19G5 were isolated, lysed in HBS containing 0.5% NP40 and protease inhibitors. CD23 was then precipitated with 2H10-affi and visualized by
western blot. For comparison, total CD23 was isolated from the same cells by
immunoprecipitating CD23+-CHO NP-40 lysates with 2H10-affi. The blots are
representative of at least two experiments of similar design.
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Figure 31: CD23 was cleaved in exosomes in an ADAM10 dependent manner. (A)
Exosomes from RPMI 8866 supernatants were isolated and either lysed directly in SDS
or resuspended in MES buffered saline (pH 5.8) plus 1% serum and cultured at 37ºC for
either 5 or 30 sec. Cultures were then neutralized with tris buffer pH 8.0 and CD23 was
immunoprecipitated with IDEC-152 (humanized anti-CD23 lectin), and analyzed for
CD23 by western blot. (B) Exosomes were isolated and treated as in a, except this time
they were resuspendend in normal RPMI buffer plus serum pH 7.4 and cultured at 37 ºC
for 30 minutes, 1 hour and 17 hours. CD23 was then precipitated with IDEC-152 and
analyzed for cleavage products by western blot. (C) Exosomes from surface biotinylated
RPMI 8866 were isolated and resuspended in media ± 10 µM of ADAM10 inhibitor
(INC008765) and incubated at 37ºC for 17 hours. Biotinylated proteins were then
precipitated using avidin-agarose and analyzed for CD23 by western blot.
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Figure 32: A Large percentage of sCD23 is exosome bound. (A) CD23 from RPMI
8866 cell free supernatant or supernatant where exosomes had been removed were
precipitated with IDEC-152 and compared to CD23 from exosomes via western blot.
The blots are a representative of at least two independent experiments. (B) CD23+-CHO
cells were treated with CoH2 (rat IgG control), IgE or 19G5 for 24 hours. Supernatant
was then isolated and exosomes were removed, then by ELISA the amount of sCD23 was
measured in the supernatant or exosome free supernatant and compared. Shown is the
average of three experiments. Error bars represent standard deviation. * = P value < .05
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Figure 33: ADAM10 binding of CD23 was essential for sorting into Exosomes. (A)
Purified mouse B-cells were isolated by fluorescence activated cell sorting using antiB220. They were then stimulated with LPS/IL-4 for three days. Exosomes were then
isolated from the supernatant and analyzed for CD23 and MHC class II expression. (B)
Equal amounts of mCD23+-CHO cells were treated overnight with normal IgG or
antibodies that either stabilize (IgE) or destabilize (19G5) CD23. Exosomes were then
pelleted and analyzed for the amount of CD23 by western blot. Shown is the average
relative density of four independent experiments. (C) RPMI 8866 was grown for 24 hours
in the presence of 10 µg/ml of either Coh2 or IgE. After 24 hours exosomes were
isolated and analyzed by western blot for CD23 presence as explained in the material and
methods. Shown is the average of three experiments. (D) mCD23+-CHO cells were
cultured ± 10 mM NH4Cl and destabilizing antibody (19G5) overnight; exosomes were
then isolated and examined for the presence of CD23 by western blot. Each blot is a
representative of at least three independent experiments. Error bars represent standard
deviation.
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C. Full length CD23 is incorporated into exosomes - Recent reports have
shown that multiple surface bound proteins, including MHC class I and II, and the B cell
receptor can be internalized and released from cells in the form of exosomes (76). To
determine if CD23 was also incorporated and/or released in exosomes, standardized
numbers of RPMI 8866 cells were pelleted and exosomes were isolated from the cell free
supernatants by ultracentrifugation as indicated in the experimental procedure. The pellet
was resuspended and subjected to sucrose density gradient ultra-centrifugation. Fractions
were collected and examined by western blot (Figure 30a). CD23 was found localized to
the 1.12-1.16 M sucrose region, which is where exosomes are known to be found (70).
The 1.3-2 M sucrose region, where membrane blebs localize, did not contain CD23. As
exosomes have been shown to express ADAM10 (120), as a positive control the same
fractions were also stained with anti-ADAM10 and a 60 kD protein, which corresponds
to mature ADAM10, was detected (Figure 30b). Thus, both ADAM10 and CD23 were
clearly associated with exosomes. Note that the CD23 is full length in that the molecular
weight (mw) is 45 kD the same as that precipitated directly from cell lysates (Figure 30c).
This would be expected, since membrane CD23 would be incorporated. Figure 30d
represents an experiment where full length mouse CD23, from CD23+-CHO cells is also
shown to be found in exosomes. For Figure 30d, CD23 internalization was first
stimulated by 16 hr culture with the anti-stalk antibody, 19G5. The higher mw of the two
bands corresponds to full length CD23 (see Figure 30d) and this band is also seen when
examining biotinylated CD23 isolated from cell surface biotinylated cells (not shown).
The identity of the lower molecular weight band corresponds to endoH insensitive CD23
(121), and is thus presumably newly synthesized CD23. This band is not seen when
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exosomes are isolated from either B cell lines or primary B cells (Figures 30a and 34a)
but is only found in transfected cells (Figures 30c and 35) thus is most likely an artifact
not seen in primary cells. Note also that CD23 inclusion in exosomes is not just an
artifact of transformed cells as CD23 was also found associated with exosomes from
primary mouse B cells (Figure 33a), nor is it specific to one species, as CD23 containing
exosomes are secreted from both human and mouse B cells.
D. Demonstration of ADAM10 dependent cleavage of exosome CD23 - As the
size of CD23 found in exosomes corresponded to full length CD23 (Figure 30c), we
examined CD23 cleavage by ADAM10 post exosome incorporation. Exosomes from
cultured RPMI 8866 cells were isolated from the supernatant and then resuspended for
different periods of time in MES buffered saline (50 mM MES, 100 mM NaCl) (pH 5.8)
or RPMI (pH 7.4) containing heat-inactivated fetal calf serum. After neutralization, all
samples were kept on ice and CD23 fragments were isolated and examined by Western
(Figure 31a and b). The results were quite striking. When the exosomes were
resuspended in pH 7.4 there was minimal cleavage, even after overnight culture at 37°C.
In contrast, the initial 37 kD cleavage fragment is rapidly apparent if the exosomes are
resuspended at pH 5.8, which mimics endosomal conditions. Not all of CD23 is cleaved,
which explains why some of CD23 is still released in the context of exosomes. Note also
that the primary cleavage fragment observed is the first CD23 fragment reported by
others (122). Some additional cleavage to 33 and 25 kD is seen, but this is relatively
minimal. Inclusion of ADAM10 inhibitor in the exosome suspension blocked cleavage at
pH 7.4 (Figure 31c). The data thus demonstrates that ADAM10 is much more active at
endosomal pH and suggests that some CD23 cleavage would take place before the
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exosomes are released from the cell. In addition, CD23 fragments were isolated from cell
supernatant and exosome free supernatants using anti-CD23, and examined by western.
In the exosome free supernatants the primary fragments were the 33 and 25 kD isoforms
(Figure 32a), while in the complete cell supernatant a 45 kD isoform was also found.
This larger fragment is most likely exosome bound. Finally when the amount of sCD23
found in exosomes versus the exosome free supernatant in CD23+-CHO culture were
compared the majority was found in the exosome fraction (Figure 32b). These results
demonstrate that ADAM10 dependent cleaved fragments of CD23 seen in B cell cultures
originates from the cleavage of exosome associated CD23 after intact CD23 was sorted
into exosomes. The data further suggest that the later CD23 fragmentation primarily
occurred post-exosome release and are probably ADAM10 independent. This hypothesis
of the later fragmentation being ADAM10 independent is in agreement with previous
findings (48).
E. ADAM10 was essential for sorting of CD23 into exosomes - Previously (50)
B cells that lack ADAM10 were shown to have dramatically increased CD23 on the cell
surface. In addition, the treatment of these cells with destabilizing antibodies did not
cause an increase in cleavage (50) compared to WT. This indicates that ADAM10 might
be important not only for cleavage of CD23, but also for sorting CD23 into exosomes. As
seen earlier, (Figure 30d), full length mouse CD23 is also included in exosomes. Thus, to
test our hypothesis that ADAM10 is required for inclusion in exosomes. B cells from
CD19-cre+/--ADAM10flox/flox (ADAM10-/-) mice and Cre-negative littermates, used as
WT control, were isolated and stimulated with LPS plus IL-4 for three days. Exosomes
were then isolated and the presence of CD23 was determined by western blot (Figure
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33a). In both cases exosomes were secreted, as seen by the presence of MHC class II,
however in the exosomes derived from the ADAM10-/- B cells, CD23 was not present. In
addition, Figure 33b demonstrates that enhanced CD23 incorporation into exosomes is
observed under destabilizing (19G5) conditions, compared to stabilized (IgE) or control
(normal IgG). Additionally, when RPMI 8866 cells were treated with either IgE (JW8) or
Ig control (Coh2), IgE decreased the incorporation of CD23 into exosomes (Figure 33c).
Finally, CD23 inclusion in exosomes could also be blocked by culturing mCD23+-CHO
cells in the presence of NH4Cl (Figure 33d). Overall, the data of Figure 32 and 33 suggest
that CD23 is first incorporated in the MVB into exosomes, and secreted as intact
exosome bound CD23. However, at endosomal pH, rapid ADAM10 dependent cleavage
occurs. Once released, the initial cleavage is much more gradual, but is still ADAM10
dependent. These results thus showed that ADAM10 is essential for CD23 inclusion in
exosomes, most likely through their direct interaction. These results, also demonstrate
that a change in internalization of CD23 (see Figure 27c) would be reflected in the
amount of CD23 in exosomes.
F. The interaction of ADAM10 and CD23 - We next sought to understand the
mechanics of the ADAM10-CD23 interaction. All previously known ligands of CD23,
including IgE, CD11, CD18 and CD21, bind CD23 in the lectin head. ADAM10 binds
its substrates in a protease independent manner, where binding takes place in the
disintegrin or cysteine-rich regions (67). To investigate the binding sites of ADAM10
and CD23 an in vitro assay was used where recombinant trimerized mouse CD23 was
trapped on nitrocellulose in a dot blot approach. Then after blocking with nonspecific
proteins, ADAM10 was allowed to interact. The ADAM10 protein used for binding was
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Figure 34: CD23 and ADAM10 binding can be detected by Dot blot (A) lz-mouse
CD23 starting at 1 mM in PBS was serially diluted 1:2 across the dot blot apparatus and
trapped on the nitrocellulose by applying vacuum. Membranes were then removed and
blocked in 5% milk in 1X HBS containing 0.05% Tween-20. In the upper western the
binding of CD23 is demonstrated. ADAM10 cell lysate from 293-F cells transiently
expressing mADAM10-HA was then added to similar CD23 coated membrane and
allowed to incubate for 18 hrs at 4°C and then washed. ADAM10 binding was then
measured using a Rabbit antibody against the C terminus end of ADAM10 and a HRPGoat anti-rabbit IgG. In the lower blot, as a negative control BSA starting at 1 mM
(shown to bind equally to the blot using Ponceau S staining) was added instead of CD23.
(B) lz-human CD23 and cell lysates from 293-F expressing human ADAM10 was used as
in a, to confirm that CD23 and ADAM10 in the human system also bind. (C)
mADAM10-DN was used instead of full length ADAM10 and binding to CD23 was
confirmed using the same antibodies as used in A and B. Each blot is a representative of
at least three independent experiments.
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Figure 35: ADAM10 and CD23 co-precipitate from overexpressing cells. 293-F cells
were transfected with mouse CD23 and mADAM10-HA. Then 48 hours later cells were
lysed in 50 mM MES, 110 mM NaCl pH 5.8 containing protease inhibitors and 0.5%
NP40. Cell lysate were spun to remove nuclei, and then split into 3 equal parts for IP and
cell lysate. For IP 10 µg/ml of either 2H10 (rat anti-mouse CD23) or Rabbit anti-HA
were added to the cell lysate and nutated at 4°C for 30 minutes, protein A/G was then
added and nutated for an additional 30 minutes and then washed three times with HBS.
Finally precipitated proteins were isolated by boiling the protein A/G bound proteins in
SDS buffer and reducing agent for 10 min and resolved on SDS-Page. CD23 and
ADAM10 were then detected with Rb anti-CD23 antibody followed by protein A/G-HRP
or a mouse anti-HA antibody followed by a Goat anti-Mouse-HRP antibody respectively
and compared to unfractionated cell lysate.
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Figure 36: ADAM10 binds the stalk region of CD23 (A) Mutant forms of CD23
(numbers indicate amino acids included) to determine where ADAM10 bound CD23
were added to the dot blot apparatus as explained in Figure 34 and binding was compared
to the full length. (B) Shown is the relative density of the respective spots and is the
average of two experiments. (C) Full length CD23 on blot was either stabilized or
destabilized by incubation with IgE and 19G5 respectively, prior to the addition of
ADAM10 and binding was compared to the untreated control; shown is the average
relative density of three independent experiments. Error bars represent standard
deviation.
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Figure 37: SPR shows ADAM10 and CD23 have a higher rMAX at low pH. (A) Dose
response of rCD23 diluted in MES (pH 5.8) binding to rADAM10 bound to the CM5
chip. (B) Comparison of binding of rCD23 and rADAM10 when diluted in either MES
(pH 5.8) or HEPES (pH 7.4). Shown is binding when 100 µg/ml of rCD23 was used.
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Figure 38: Analysis of SPR. 5-100 µg/ml of rCD23 diluted in either HEPES or MES
buffer was flowed over chip bound rADAM10 as explained in Figure 37. Then using the
SPR software the affinity and Rmax were determined using either (A) stead state analysis
or (B) conformation change analysis. Error represents standard deviation.
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Figure 39: Proof of conformation change. To confirm that a conformation change was
taking place between CD23 and ADAM10, 50 µg/ml diluted in MES (pH 5.8) and was
flowed over rADAM10 for different periods of time (175, 500, 750, 1000, 1500 seconds).
Off rates were then compared. (A) Dissociation curves (B) Dissociation rates. n=1
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from the cell lysate of 293F cells overexpressing ADAM10. After washing, bound
ADAM10 was detected using anti-ADAM10. Using this approach we first demonstrated
that the CD23-ADAM10 interaction could be determined in this manner (Figure 33a),
and confirmed previous data ((48) and Figure 35), that found that CD23 and ADAM10
were co-precipitated in overexpressing cells. Using the dot blot approach we also showed
that human CD23 and ADAM10 also interact (Figure 34b). Next, to determine the
regions of ADAM10 and CD23 important in binding, mutant recombinant fragments of
ADAM10 and CD23 (where either the lectin head or sections of the stalk region of CD23
were removed) were used in the dot blot approach. For ADAM10 lysate from cells overexpressing DN-ADAM10 (123) was used and showed that ADAM10 binds CD23 in a
protease independent manner (Figure 34c). For CD23 the mutant recombinants (shown
in Figure 8) binding of ADAM10 were compared to full length CD23 (Figure 36a and b).
The samples tested were lz-CD2386-331, which represents full length trimeric CD23 (41);
lz-CD23139-331, which was the mutant form that still contained the ADAM10 cleavage site
and still interacted normally with IgE (41); CD2348-171, which is the stalk region alone;
and lz-CD23171-331, which lack the ADAM10 cleavage site and no longer interacts with
IgE (41). In contrast to IgE and other CD23 binding partners that require the lectin head
for binding, the CD23 stalk alone bound ADAM10; showing that ADAM10 binds in the
stalk region of CD23. Data from the other mutant fragments showed that this binding
takes place between amino acids 139-171 of CD23. These data help explain earlier
studies that indicated that polyclonal rabbit anti-stalk blocked CD23 cleavage (40). This
demonstrated that ADAM10 binds CD23 similar to how it does its other substrates,
namely in a protease domain independent manner.
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The dot blot approach was also used to determine if destabilizing (19G5) or
stabilizing IgE reagents would influence the interaction of ADAM10 and CD23. As is
seen in Figure 36c, 19G5 did not alter the level of interaction, further supporting the
concept that “destabilization” really reflects increased internalization. Intriguingly, IgE
did partially block the interaction of ADAM10 and CD23. This suggests that IgE inhibits
CD23 cleavage in a dual manner, both by keeping CD23 at the cell surface (Figure 27c)
and blocking ADAM10 interaction directly (Figure 36c).
To extend and confirm the interaction data SPR analysis was used. Recombinant
ADAM10 was immobilized on a CM5 chip and allowed to interact with recombinant
CD23. The soluble CD23 that was used was lz-CD23139–331, which was shown previously
to be the minimal amount of stalk to refold in a trimeric form capable of interacting with
IgE (41). In addition, this was the minimal amount of stalk needed for ADAM10 binding
(Figure 36b). As ADAM10 dependent CD23 cleavage was enhanced at endosomal pH
(Figure 31a), CD23 was dissolved in either pH 5.8 (the pH of MVB (119)) or
extracellular expected pH of 7.4. A dose response was seen for binding of CD23 and
ADAM10 (Figure 37a). Steady state affinity measurements were not significantly
different when comparing the values obtained at either pH (Figure 38a); however, the
Rmax value was about an order of magnitude higher at pH 5.8. An example sensogram
comparison at the two pH values is shown in Figure 37b. The large increase in Rmax
indicates that the sites of interaction in CD23 and ADAM10 are more accessible at the
lower pH, while the similar affinities indicate that once accessible, the binding strengths
are not significantly different.
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To attempt to determine the type of interaction that occurs between CD23 and
ADAM10, several different models were used including 1:1, bivalent and conformation
change binding. Conformation change was determined to have the best fit as determined
by the Chi-squared value. To confirm that at the lower pH, CD23 and ADAM10 are truly
undergoing a conformation change, and cause the higher Rmax, previously a method was
developed by Lipschultz and Smith-Gill (107). They showed that proteins can interact in
two states, either the state where conformation change has not taken place or after
conformation change takes place. This change in conformation can be seen as a change
in off-rate over time. Thus the same concentration of CD23 can be flowed across
rADAM10 for increasing time periods and the off-rates can then be compared to
determine if a conformation change is taking place. As shown in Figure 39a, this is
exactly what we found. When the off rate was determined using the biacore software
(Figure 39b) there was about a 35% change in off-rate when more of the proteins were
interacting after conformation change. When the affinity and Rmax were then analyzed
with conformation change analysis, we found similar results about the CD23 and
ADAM10 interaction as we did with steady state analysis (Figure 38b) that lower the pH
increased the Rmax but not the affinity.
G. Function of CD23 in Exosomes: Previously Ford et al. (87) showed that the
injection of 19G5 into mice increased the cleavage of CD23 and IgE synthesis when
given in combination with antigen. As we have showed in Figure 27c and 33b, 19G5
causes increased production of sCD23 by increasing the internalization and thus inclusion
in exosomes. We thus hypothesized that the mode of action of 19G5 worked in vivo is to
increase the levels of CD23+-exosome in serum. These exosomes could then bind the
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Figure 40: CD23 is not contained in exosomes 5 days after 19G5 injection in vivo.
As previously shown in (87) when 19G5 is injected in mice there is a large increase in
sCD23. To determine if this sCD23 was mostly exosome bound as we found in vitro,
19G5 was injected IP into WT BALB/C mice on days 0 and 2 then 3 days after the final
injection mice were sacrificed and cardiac punctured. The exosome fraction from the
serum was then isolated and compared to the non-exosome fraction for CD23 expression
by western blot. 19G5 was injected into two different animals and both are shown.
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minimal IgE bound to antigen; these exosomes would then be taken up by dendritic cells
and increase antigen presentation, leading to increased T cell response, cytokine
production and IgE synthesis. To test this BALB/C mice were injected with 19G5 on
days 1 and 3 and then on day 5 mice were bled and serum was collected. The serum
was then fractionated into exosome and exosome-free fractions and CD23 was purified
and analyzed by western blot. Unfortunately, all of the CD23 was found in the exosomefree fraction (Figure 40). This could be because by day 5 all of the exosomes had either
been phagocytosed or cleaved by serum proteases.
III. Cytokine increase of ADAM10 could potentially be affecting IgE production.
In the above two sections, we have shown that inhibiting ADAM10 blocks IgE
dependent disease potentially in two ways. First off, as cell surface bound CD23 is
increased there is a corresponding decrease in IgE. Secondly, as ADAM10 is required
for sorting CD23 into exosomes, which are potentially involved in increasing immune
reactions, inhibition of ADAM10 would decrease inflammation. As stated earlier,
ADAM10 is also known to be increased in the context of inflammation (83). These data
thus show that increases ADAM10 levels could potentially also increase the
inflammatory response, and thus shows that understanding what effects the expression of
ADAM10 is important.
A. Effects of cytokines on ADAM10 expression. Previously Prinzen et al. (108)
has shown that retinoic acid can increase the activity of the ADAM10 promoter. In B
cells it is known that activation increases CD23 expression, then after class switching
there is a loss of CD23 from the cell surface (124). We would thus hypothesize that
ADAM10 levels might follow the same expression pattern. Using bioinformatics, we
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Figure 41: Confirmation that clone #4 has highest Luciferase activity. After
transfection of RPMI 8866 and drug selection, cells were plated at a single cell/well.
Then multiple clones were screened for their expression of Luciferase activity, shown are
two of these clones.
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Figure 42: IL-4 only transiently changes ADAM10 expression and promoter
activity. RPMI 8866 stably expressing the Luciferase gene under the control of the
human ADAM10 promoter were stimulated with (A) 10 ng/ml of IL-4 and promoter
activity was compared and normalized to unstimulated cells (shown is only the activity
after stimulation with IL-4). (B) Promoter activity was determined after stimulation with
10 ng/ml of IL-13. Shown is only curve that has been normalized to promoter activity in
unstimulated cells. (C) Primary B cells were stimulated with IL-4 alone and mRNA was
isolated at different time points and compared to unstimulated cells using qRT-PCR as
explained in the material and methods. Error bars represent standard deviation.
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Figure 43: IL-21 increases promoter activity and mRNA expression. RPMI 8866
stably expressing the Luciferase gene under control of the ADAM10 promoter as
explained in figure 41, were stimulated with (A) 25 ng/ml of IL-21 and compared to
unstimulated cells. Shown is the average of two experiments. (B) Primary B cells were
stimulated with 25 ng/ml of IL-21 alone or left unstimulated for 8 hours. mRNA was
then isolated and ADAM10 levels were determined by qRT-PCR. Experiment was
preformed once. Error bars represent standard deviation.
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Figure 44: anti-CD40 also increases promoter activity, sCD23 and ADAM10 protein
levels. RPMI 8866 stably expressing the luciferase gene under the ADAM10 promoter as
explained in Figure 41 were stimulated (A) with anti-CD40 for 8 hours, and then
compared to unstimulated control. To determine if this signaling was through the NFκB
pathway in parallel experiments the Bay inhibitor was included at a concentration of 1
μM, n=1. (B) To determine if anti-CD40 also increased ADAM10 activity, RPMI 8866 at
50,000 cells/well were stimulated with anti-CD40 then 24 hours later the supernatants
were collected and compared to unstimulated cells used as a control. (C) To determine if
IL-21 and/or CD40 signaling were also having an effect on ADAM10 protein levels.
RPMI 8866 cells were stimulated with anti-CD40 and IL-21 and then 24 hours later
ADAM10 levels were determined by flow cytometry as explained in the material and
methods. Error bars represent standard deviation.
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found that the human ADAM10 promoter contained several putative transcriptional
factor binding sites, including GATA1, 2 and 3, Statx and NF-κ. Also in the studies by
Prizen et al. (108) she had found that at least in HEK293 cells the region between 300
and 433 upstream of the transcriptional start site were most important for ADAM10
promoter activity. Thus we hypothesized that cytokines such as IL-4 which signaling
causes the phosphorylation of Stat6 could possibly be regulating ADAM10 expression.
The human ADAM10 vector, graciously provided by the Prinzen laboratory, was used to
transfect RPMI 8866 cells to test our hypothesis that cytokines change ADAM10
promoter activity and ultimately expression. Transfected cells were then cultured with IL4 (Figure 42a), IL-13 (Figure 42c), IL-21 (Figure 43) and anti-CD40 (Figure 44) to
determine their respective effects on the ADAM10 promoter. As a control, cells were
dually transfected with a vector expressing Renilla Luciferase to standardize our samples.
Twenty-four hours after stimulation, promoter activity was determined and compared to
unstimulated cells. These results (not shown) showed us initially that cytokines do have
effects on ADAM10. However, transient transfection does not allow studying of the
promoter beyond about 2 days. Additionally, with each transfection there is a difference
in efficiency, thus making it hard to compare results. We therefore created a cell line
stably expressing the luciferase gene under control of the ADAM10 promoter. These
cells were then stimulated with the different cytokines stated above and compared to
unstimulated cells. IL-4 was found to transiently decrease the promoter activity (Figure
42a), which also corresponded to a slight transient decrease in the mRNA levels (Figure
42b). Previously it was also found that IL-4 does not have an affect on protein levels of
ADAM10 (48). Similar results were also found with IL-13 (Figure 42c). In contrast to
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IL-4, IL-21 increased ADAM10 promoter activity as well as mRNA level (Figure 43a
and b). Additionally we also found IL-21 increased the expression of ADAM10 (as seen
by FACS (Figure 44c)). Anti-CD40 also increased ADAM10 promoter activity. This
increase could be blocked by the addition of 1 μM of Bay inhibitor (11-7082, blocks IκB
phosphorylation) (Figure 42a), thus showing that anti-CD40 was increasing ADAM10
promoter activity through NFκB signaling. Anti-CD40 also increased the levels of
ADAM10 mRNA (Figure 44b) and protein expression (as seen by FACS (Figure 44c)).
A caveat to these studies is that unstimulated RPMI 8866 have high levels of ADAM10,
thus making it difficult to determine if the addition of cytokines was causing significant
difference. Overall this data shows that some cytokines and membrane bound proteins
can increase ADAM10 expression.
B. Effects of ADAM10 inhibitors on immunoglobulin production.
We found that inhibition of ADAM10 decreased IgE in the BALF compared to
DMSO treated mice (Figure 21e) as well as the signs of experimental asthma (Figure 21).
Additionally, we also found that cytokines affect the expression ADAM10. We thus
sought to determine if blocking ADAM10 with an inhibitor would decrease the IgE
production of primary tonsillar B cells cultured in activating condition. First to determine
the correct concentration of inhibitor to use in these studies, we tested sCD23 release
using increased doses of inhibitor. B cells were incubated for 5 days plus or minus three
different inhibitors, the Glaxo ADAM10 inhibitor, the Incyte ADAM10 inhibitor or the
Incyte ADAM17 inhibitor (included as a negative control) (Figure 45a). We found the
Incyte ADAM10 inhibitor had an IC50 in the range of 5 µM, this concentration is very
selective for ADAM10 (91). For the Glaxo ADAM10 inhibitor the IC50 was about 1.25
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Figure 45: Dose response of ADAM10 inhibitors. (A) Primary B cells plated at 50,000
cells/well stimulated with 10 ng/ml of IL-4, 200 ng/ml of IL-21 and 1 µg/ml of antiCD40 were cultured with different doses of either the Incyte or Glaxo ADAM10
inhibitors or the Incyte ADAM17 inhibitor (as ADAM17 is known not to be involved in
CD23 cleavage, this inhibitor was used as a negative control) in order to determine the
correct dose of inhibitor to inhibit sCD23 release. Supernatant was isolated after 5 days
of culture and sCD23 levels were tested by ELISA and compared to control untreated
cells. (B) Similar experiment as in A except cells were plated at 12,500 cells/well and
isolated at day 14 and tested for immunoglobulin production by ELISA. Error bars
represent standard deviation.
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Figure 46: ADAM10 inhibitors decrease sCD23 and IgE but not proliferation. (A)
Primary B cells plated at 12, 500 cells/well were stimulated as explained in Figure 45b
+/- the Incyte ADAM10 inhibitor (INC008765) (10 µM). Production of immunoglobulin
and sCD23 as measured by ELISA were normalized to the cells treated with equal
amounts of DMSO and then averaged. Proliferation was determined by H3-thymadine
incorporation as explained in the Material and methods and was again normalized to cells
treated with DMSO. (B) (ADAM10 is referred to as AD10 in this panel) Similarly to A
except this time peripheral blood mononuclear cells (PBMC) isolated from whole blood
as explained in the material and methods were plated at 300,000 cells/well and again
stimulated with IL-4, IL-21 and anti-CD40 were used. Levels of IgE production were
then measured on Day 14 and compared to DMSO treated cells. Shown is the average of
three experiments. (C) To determine if inhibition of ADAM10 was affecting cell division,
primary tonsilor B cells were stained with CFSE prior to being plated at 12,500 cells/well
and stimulated with IL-4, IL-21 and anti-CD40. On day 5 cells were isolated and the
number of cell division was then determined by flow cytometry as explained in the
material and methods. Error bars represent standard deviation. * = P value < .05, ** = P
value < .01.
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Figure 47: The number of IgE secreting cells is unaffected by the addition of
ADAM10 inhibitors. (A) Primary tonsilor B cells were plated and stimulated as
described in figure 45b and immunoglobulin levels were determined by ELISA. (B)
Using cells isolated from the same tonsil as in A in a parallel experiment, cells were
plated in triplicate at three different concentration as indicated in the figure and
stimulated. Then on day 8 of the culture the cells were isolated and washed and
restimulated with IL-4, IL-21 and anti-CD40. They were then replated on MultiScreen
Filter plates pre-coated with mouse anti-human IgE (4.15) (5 µg/ml) and grown for 20
hours. Plates were then developed as explained the material and methods and spots
(which indicates the number of IgE producing cells) were counted. (C) Same as B except
with B cells were isolated from a second tonsil. Error bars represent standard deviation.
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Figure 48: sCD23 does not rescue the ADAM10 inhibitor effect on IgE synthesis. B
cells were stimulated +/- the ADAM10 inhibitor as explained in figure 45b. To
determine if the decrease in immunoglobulin production was because of decreased
sCD23, 2 µg/ml (approximately the decrease in sCD23 seen in cultures with the inhibitor
compared to the vehicle control as determined by ELISA) of sCD23 (isolated from RPMI
8866) was added to the cultures treated with the ADAM10 inhibitor. Then on day 14 (A)
IgG or (B) IgE levels were determined by ELISA. (C) To determine when ADAM10 was
important in the production of IgE, the inhibitor was added on days 0, 5, and 8 of the
culture and IgE levels were determined by ELISA on day 14. Shown are results from one
experiment.
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µM, however concentration above 2 µM are considered to not be selective for ADAM10
(125). When these same cultures were extended to 14 days and immunoglobulin levels
were measured (Figure 45b), we found that blocking ADAM10’s ability to cleave
decreases the production of IgE. However, although the Glaxo inhibitor is was more
effective at inhibiting IgE, it required levels that were not selective for ADAM10. Thus,
most of the further studies were only done with the Incyte ADAM10 inhibitor. Figure
46a shows a combination of multiple experiments with the Incyte ADAM10 inhibitor (10
µM) and shows that inhibiting ADAM10 decreases IgE synthesis on average by about
50%. The same decrease is also seen when purified PBMC plated at 300,000 cells/well
were used (Figure 46b).
It has previously been shown in both the mouse and human system that to class
switch to IgE B cells must go through multiple rounds of cell divisions (15;126). Thus it
is possible that inhibiting ADAM10 is decreasing cell division. To test this hypothesis
tonsillar B cells +/- the Incyte ADAM10 inhibitor were cultured for 4 days. They were
then pulsed as explained in the material and methods with H3-thymidine. 24 hours later
the cells were harvested and incorporation was measured. As shown in Figure 46a, the
inclusion of the ADAM10 inhibitor as measured by H3-thymidine had no effect on
proliferation, while with CFSE (Figure 46c) there is a slight increase in cell division.
Thus ADAM10 inhibition having little effect on the proliferation of B cells.
Another possibility is that ADAM10 inhibition is affecting B cell class switching.
This possibility would seem to make sense as inhibiting ADAM10 also slightly decreases
IgG production (Figure 46a). To test this, the amount of B cell producing IgE +/- the
ADAM10 inhibitor was determined by elispot as explained in the Materials and Methods.
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As is shown in Figure 47, opposite to what we expected, inhibiting ADAM10 had no
effect on the amount of cells that produced IgE. These results thus show that ADAM10
has no effect on class switching, but that inhibiting ADAM10 decreases the production of
IgE on a per cell basis.
Previously McCloskey et al. showed that if sCD23 is added to tonsillar B cells it
can either increase IgE production or decrease based on oligomerization state of CD23
(127) . If it is a monomer it decreases IgE. If it is an oligomer it increases. They
proposed that the ability of oligomers to increase IgE was due to trimeric CD23 ability to
cross-link CD21 and mIgE on B cell. With the addition of the ADAM10 inhibitor we
would be blocking sCD23 release, and possibly this sCD23 is needed to increase the
production of IgE. To test this, we isolated sCD23 from RPMI 8866 cells and then
determined its concentration by ELISA. It was then added to ADAM10 inhibited B cell
cultures at a concentration of 2 µg/ml, which is the concentration we determined would
be in cultures without the inhibitor. The sCD23 isolated from RPMI 8866 would be a
mixture of monomers and oligomers, however as we showed in Figure 34a it is
predominately composed of oligomers and would be expected to stimulate IgE
production. However, we found that the addition of sCD23 could not reverse the effects
of ADAM10 inhibition (Figure 48a, b). As the sCD23 we added back was a mixture of
both monomeric and trimeric (see Fig 32a) the lack of reverse could be because it
contains monomeric sCD23, which cannot crosslink CD21 and mIgE. But as this is the
type of sCD23 mixture that the B cells cultures themselves would contain we can
conclude that the reason that ADAM10 activity is important in IgE production is not
because it increases the levels of sCD23.
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Finally, Mayer et al. also showed previously with a broad spectrum inhibitor of
metalloproteases, that metalloproteases activity is only needed early in the cultures. If the
inhibitors were added at later time points in the cultures, the inhibition of IgE was not as
pronounced (128). When we performed a similar experiment with the ADAM10
inhibitors we found the same thing (Figure 48c). ADAM10 was most important early in
the cultures however later it was not as important. Mayer et al. also found that the
inhibition pattern exactly paralleled that of anti-lectin antibodies. This suggests that
membrane bound CD23 early in the cultures is important for controlling the switching of
cells to high IgE producers but not in class switching (128). Overall, this data shows that
ADAM10 is important in the early stages of in vitro B cells cultures, and increases IgE
synthesis on a per cell bases. This increase however is not because it increases the levels
of sCD23, but because it decreases the levels of membrane bound CD23. These results
further shows that it is membrane bound CD23 that is involved in the regulation of IgE
synthesis.
C. Knocking down ADAM10 does change proliferation
When we used the inhibitors above we found that blocking ADAM10 activity did
not have an effect on proliferation in primary B cells. However in work done by Jamie
Sturgill previously in the laboratory with a broad spectrum inhibitor of metalloproteases,
marimastat, she had found that marimastat was added to RPMI 8866 there was a decrease
in proliferation compared to untreated cells (data not shown). RPMI 8866 are a non-EBV
infected human lymphoblastoid B cell line and thus ADAM10 in these cells could have
been hijacked and be involved in the continual growth of these and other malignant B
cells, while it is not in primary B cells. To test this hypothesis, RPMI 8866 were
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Figure 49: Knocking down ADAM10 with siRNA decreases the proliferation of
RPMI 8866. ADAM10 mRNA levels were knocked down in RPMI 8866 by the
transfection with the plasmid shown in figure 12 as explained in the material and
methods. Cells were also co-transfected with a GFP expressing plasmid. GFP+ cells
were then sorted. (A) mRNA from these cells were then isolated and ADAM10 mRNA
levels were compared to cells only transfected with the GFP plasmid by RT-PCR. (B)
Shown is the average of at least three experiments. (C) In parallel experiments sorted
cells were plated at 50,000 cells/well and proliferation was determined by H3
incorporation as explained in the material methods. Shown is the average of three
experiments.
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Figure 50: Doxycycline decreases ADAM10 expression and kills RPMI 8866. (A)
RPMI 8866 cells were transfected with two plasmids shown in Figure 13 and selected for
with Blasticidin and G418 to create a inducible stably expressing siRNA cell line. The
siRNA is induced by the addition of doxycycline. To ensure that doxycycline it self was
not affecting RPMI 8866, ADAM10 levels were determined by qRT-PCR after the
addition of increased amounts of doxycycline and compared to untreated cells. (B)
Proliferation as determined by H3- thymidine incorporation was determined following the
addition of increasing amounts of doxycycline to both the inducible cell line plus
untransfected RPMI 8866. These results are from one experiment.
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transfected with a siRNA plasmid (Figure 11) and then tested for the amount of
proliferation compared to cells transfected with a plasmid containing a scrambled siRNA.
As B cells have very low transfection efficiency, RPMI 8866 were co-transfected with a
GFP constitutively expressing plasmid along with the siRNA plasmid (Figure 11).
Twenty-four hours later GFP positive cells were sorted. The cells were then collected
and mRNA was isolated. As is shown in (Figure 49a and b) siRNA caused an 80%
knock down of ADAM10 mRNA. In parallel experiments after sorting, the cells were
plated and proliferation was measured by H3-thymidine incorporation (Figure 49c). We
found that knocking down ADAM10 decreased proliferation by about one-third and thus
confirmed our hypothesis that in a least in this malignant B cell line ADAM10 has been
hijacked and is involved in increasing the cells proliferation.
As all these studies were done using transiently expressed siRNA, we did not
have much control over the levels of siRNA expression. In addition, as the B cells had to
be transfected each time there was some cell death associated with the transfection. We
tried to control for this by always comparing our results to sorted cells transfected with
just GFP or a scrambled siRNA/GFP. However, a better way is to create a stable tet-on
siRNA cell line using the vectors shown in Figure 12. Unfortunately, we quickly learned
that this would not work, as the inducer of the siRNA, doxycycline, decreased ADAM10
levels as well as the proliferation of the cells by itself (Figure 50a and b). Overall, the
results in Figure 49 in combination with the inhibitors studies show that ADAM10 is
involved in proliferation of at least one malignant B cell line and IgE production from
PBMC or B cells.
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Discussion
I. ADAM10 activity increases asthma induction in IgE dependent, but not IgE
independent models of experimental asthma. It has previously been shown that if the
cleavage of CD23 is blocked with a stabilizing antibody or if CD23 is overexpressed that
the signs of lung inflammation were decreased (53). However, it was not known what
role ADAM10 played in this or how CD23 was able to control lung inflammation.
Herein we show that overexpression of CD23 or blocking ADAM10 decreases the Th2
response as well as the other signs of lung inflammation, including eosinophilia, AHR
and IgE production.
Based on the findings reported we propose three possibilities of how ADAM10 is
involved in the enhancement of asthma associated signs. As we found that administration
of the inhibitor blocked IgE production (Figure 21e), this decrease in IgE would be
reflected in decreased mediators released from mast cells after antigen challenge. This
decrease in mediator release would result in decreased signs of experimental asthma,
including AHR. One of the reasons for decreased IgE production is reduced cleavage of
CD23, as we have previously shown that inhibitors of ADAM10 (109) and loss of
ADAM10 (50) reduce CD23 cleavage both in vitro and in vivo respectively.
Additionally, using a hu-PBL model in SCID mice, the inhibition of CD23 cleavage was
previously shown to correlate with decreased IgE synthesis (128). However, as discussed
earlier in mice where the B cells are deficient in ADAM10 were subjected to a model that
is dependent on IgE but not on mast cells (Model B) there still was a reduction in asthma
signs compared to WT. This thus shows that IgE must also work through other
mechanisms. This could possibly be binding of FcεR1 on basophils as they are also
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known to be increased in areas of allergic inflammation (129). Another possibility is that
the binding of IgE complexes to CD23 causes enhance antigen presentation and immune
responses. This has been well documented by the Heyman laboratory (reviewed in (60)).
As we showed in Figure 31 and 34 and will be discussed later, ADAM10 is not only the
sheddase of CD23, but also sorts CD23 into exosomes. Once released from the cell, the
CD23 containing exosomes could bind IgE complexes and cause increased antigen
presentation and T cell responses. The ADAM10 B cell conditional knockouts do not
have these CD23 containing exosomes (Figure 34a), and the lack of these CD23
containing exosomes could possibly explain part of the inhibition of the Th1, as well as
the Th2,cytokine responses. Such exosomes, containing bound IgE complexes, would be
anticipated to enhance dendritic cell activation of T cells.
Lastly as discussed above, when the ADAM10 inhibitor was administered there
was a decrease in the Th2 response. We found that this decrease could possibly be
explained by decreased IL-33 production. The transcription factor Foxa2 has recently
been shown to be one of the major regulatory proteins of lung inflammation. Mice that
lack Foxa2 have spontaneous pulmonary eosinophilic inflammation as well as mucous
production (130). Chen et al. also showed that this was because Foxa2, which is
expressed in the epithelial cells of the lung, controls the production of eotaxin and IL-33,
and thus, the Th2 response. Foxa2 has also been shown to be down-regulated by the
ADAM10 substrate EGF signaling through its receptor (131). Additionally, in asthma
patients there is an upregulation of EGFR (132) and inhibiting EGFR signaling in an
experimental mouse model shows similar results to those we found with the ADAM10
inhibitor (133). Finally, as shown in Figure 21h and 23d blocking ADAM10 did not
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cause a decrease in IL-13. We speculated above that ADAM10 cleavage of some protein
must be required for IL-13 upregulation of AHR. In the human system, Zhen et al. (131)
showed that EGFR signaling was required for both the IL-13 upregulation of mucous
production by human epithelial cells as well as constitutive mucous production. Thus
inhibition of ADAM10 could potentially be suppressing signaling through the EGF
receptor.
II. ADAM10 is also required for CD23 sorting into B cell derived exosomes. CD23
ability to be cleaved has often been termed its stability; when destabilized its cleavage is
increased while stabilizing does the converse. These results reported here help to clarify
the mechanism of this observation. Basically with the addition of IgE (stabilizing) or
19G5 (destabilizing) to CD23+ cells there is a change in internalization of CD23 (see
Figure 27c), this change is then reflective in the amount of CD23 associated with
exosomes (Figure 33b) and in soluble cleaved products. When CD23 is destabilized there
is an increased amount of CD23 associated with exosomes. Conversely when CD23 is
stabilized with monomeric IgE, CD23 associated with exosomes is decreased (Figure
33c). These results also might help explain previous findings (40) that although
destabilization was believed to cause CD23 to unravel at the cell surface, when
destabilizing antibodies were added there was no change in fluorescence resonance
energy transfer between different sections of the trimer. Thus, the data in this study
suggest that anti-stalk reagents increase internalization into endosomes. At endosomal
pH levels, the ADAM10 cleavage site is evidently much more exposed as evidenced by
the rapid cleavage when exosomal bound CD23 is resuspended at pH 5.8 (Figure 31).
When the pH is closer to neutrality (pH 7.4) cleavage is much slower. We note also that
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IgE partially inhibits ADAM10 and CD23 interaction (Figure 36c), which suggests that if
CD23 is internalized while being complexed to IgE, there would be decreased binding of
ADAM10 and thus be less efficiently incorporated into exosomes. Finally, CD23
inclusion in exosomes could also be blocked by growing CD23+-CHO cells in the
presence of NH4Cl (Figure 33d) helping to explain our results shown in Figure 28a,
where reduced cleavage is seen in the presence of this reagent. The SPR results were
also quite informative. While the steady state affinity was not significantly different at
pH 5.8 vs. 7.4, the Rmax increased about an order of magnitude (Figure 38a). This
indicates that the accessibility of the ADAM10 binding site of CD23 was greatly
increased by the lower pH, perhaps due to unraveling of the trimer at the lower pH. Most
anti-lectin mAbs result in CD23 stabilization, analogous to IgE, and decrease
internalization compared to untreated cells, and thereby also inhibit CD23 cleavage. The
mechanism responsible for internalization changes is unknown, but changing of the
conformation of the cytoplasmic domain is an intriguing possibility, as this domain was
recently shown to control internalization (118). Internalized CD23 is internalized into
clathrin coated pits and the endosomal pathway (see (36;118) and Table 2). Here
ADAM10 has a higher ability to bind CD23 as is evidence by the increase Rmax (see
Figure 37b and 38). These findings also beg the question if other ADAM10 substrates,
(e.g. notch, EGF and LAG-3) might also bind ADAM10 with a higher Rmax at a lower
pH. Once ADAM10 and CD23 interact sorting into exosomes occurs and the exosome is
either secreted with intact CD23, or the CD23 is rapidly cleaved. In addition, with the use
of an ADAM10 specific inhibitor, we showed that the first cleavages of CD23 was
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ADAM10 dependent (see Figure 31c), while subsequent cleavage were by other
proteases, which agrees with earlier published findings (48).
B cell derived exosomes are not simply a budding of the MVB or simply
fragments of the plasma membrane as their protein constituency is different than the
plasma membrane. For example, classical Fc receptors and transferrin receptors are not
found in exosomes (120). Thus, for proteins to be secreted in exosomes they require a
sort signal. Little is known about the signals required for sorting into exosomes. What is
known is that the constitutive photomorphogenesis (COP9) signalosome (CSN)
associated protein CSN5 regulates the quantity of some of the proteins in exosomes
including ubiquitinated heat shock protein 70 (134). Ubiquitination, however, is not
required for MHC II sorting into exosomes (135). For EGF receptor a one amino acid
was shown to be important for its inclusion in exosomes (120), but little else is
understood. We show that a protease, ADAM10, was essential for CD23 to be included
in exosomes (Figure 33a). Of note, although we only saw an 80% drop in sCD23 when
cells were cultured in media containing NH4Cl, this is the same percentage drop seen in
ADAM10-/- compared to WT after injection of 19G5 (50), and primary mouse B cells
cultured in the presence of inhibitors of ADAM10 (49), showing that ADAM10s
predominant role in the removal of CD23 was to sort it into exosomes. Even with the
blocking of ADAM10 there still was shedding, which shows that although in both the
human and mouse system ADAM10 cleavage in the endosomal pathway is the dominant
way of removal of CD23 from the cell there are other proteases that have this role. These
could include MMP9 (136) and ADAM8 (137) as both have been shown to be able to
cleave CD23. Finally, when calcium is influxed into the cell it causes the MVB to fuse
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with the plasma membrane and the exosomes to be released (73). Previously it was
shown that the calcium ionophore, ionomycin, increases the levels of CD23 fragments in
cell supernatant (49). Our findings may explain these findings, as ionomycin would
increase the fusing of MVB and thus the release of CD23 containing exosomes.
Once sorted into exosomes CD23 was either rapidly cleaved by ADAM10 or
secreted from the cell where cleavage by ADAM10 still occurred, albeit more slowly.
Although the exact role of CD23 in exosomes is not known: the exosomal bound intact
CD23 would retain its high affinity/avidity for IgE and thus, be able to bind both free IgE
and IgE immune complexes. Thus this pathway could represent more than just a pathway
to remove CD23 from the cell, as CD23 bound with IgE complexes represent a good
target for dendritic cells and could help explain the increased antigen presentation
capacity seen with IgE-antigen complexes (reviewed in (60)). In the case of parasite
infection or the initiation of an immune response, an increase in Ag presentation would
be advantageous, especially as exosome secretion increases with B cells activation (76).
However, in the context of Type I allergic disease, delivery of antigens to APC by
exosomal CD23 would be expected to cause increased reactions to allergens. Thus,
blocking CD23 inclusion in exosomes or release as a soluble product, analogous to IgE
(Figure 27c, 28b) is a possible allergy therapeutic strategy. As we showed in Figure 27c,
a possible way to do this is with an anti-lectin mAb or potentially blocking ADAM10
activity with an inhibitor.
As part of this study we also explored alternative ways of inhibiting CD23
inclusion in exosomes. One alternative is to keep CD23 on the surface (IgE or anti-lectin
binding), thus, preventing it from coming in contact with ADAM10. High CD23 cell
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Figure 51: Model for CD23 entering the endosomal pathway and in contact with
ADAM10. The amount of CD23 internalized is determined by its stability, with IgE/antilectin mAbs increasing internalization and anti-stalk mAbs increasing internalization.
With the decrease in pH found in the endosomal pathway ADAM10 has increased
accessibility to bind CD23 resulting in cleavage and/or sorting into exosomes. Exosome
and endosomal contents are then released from the cell; this process is enhanced by cell
activation and calcium influx.
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surface expression correlates with lower IgE synthesis. An additional alternative would
be to block ADAM10 binding. This approach would be anticipated to increase cell
surface CD23 levels; indeed B cells that lack ADAM10 were shown to have quite high
cell surface CD23 (50). These studies indicate a mechanism for this cell surface increase,
namely, ADAM10-/- B cells do not incorporate or secrete CD23 in exosomes and thus,
blocking ADAM10 binding or cleavage is a second possible therapeutic target to regulate
IgE synthesis. Although we only investigated the requirement of ADAM10 for CD23
inclusion in exosomes, we would hypothesize that ADAM10 would also be required for
the other ADAM10 substrates known to be included in exosomes, L1 and CD44 (79). In
addition, as exosomes have been shown to contained enzymatically active ADAM17 (79)
it is possible that one role of the ADAMs family members is to sort proteins into
exosomes. To block ADAM10 binding it has previously been found that an acidic pocket
of the cysteine-rich region was important for binding to Eph, with three residues being
specifically important (Glu573, Glu578, and Glu579) (25). As we found that ADAM10
bound CD23 in a protease independent manner, it is thus possible that this same region is
also important for binding CD23 (see Figure 36a and b) this region could be thus be
specifically targeted, with a small peptide or some other form of inhibitor. However, as
the Glu could potentially be protonated at the lower pH found in the endosomal pathway
this region might not be important in binding CD23 after it has been internalized. In
addition, N-glycosylation of amino acid 280 of ADAM10 has been shown to be essential
for ADAM10 shedding and sorting into exosomes. The mutation of this amino acid
caused ADAM10 to be retained in the Golgi (138), offering another target region in
blocking ADAM10’s ability to cleave CD23.

168

In summary (Figure 51), we show that CD23 internalization is affected by its
stability. Once internalized CD23 was trafficked to the MVB where ADAM10, because
of the change in pH, has increased access to bind and sort CD23 into exosomes; CD23
was then either rapidly cleaved or secreted as intact CD23 bound to exosomes. Calcium
influx enhances this exosome secretion, helping to explain the increase in sCD23
production post cell activation. Once secreted, cleavage is more gradual and the
subsequent cleavages are ADAM independent. Blocking this cleavage represents a novel
way of increasing surface CD23 and decreasing IgE synthesis.

III. Cytokine increase of ADAM10 could potentially be affecting IgE production
Hasbold et al. (126) were the first to show that class switching and synthesis of
IgE requires multiple rounds of cell division. Two recent papers from of our laboratory
have shown that signaling through cytokines or glutamate receptors can affect the amount
of B cell proliferation and IgE production. The first paper by Caven et al. (15) showed
that the addition of IL-21 both increased proliferation and IgE. In our studies we have
also shown that IL-21 (Figure 43) increases ADAM10 mRNA expression. Sturgill et al.
(109) also showed that with the addition of glutamate to B cell cultures there is a large
increase in proliferation and IgE production. She also showed that there was an increase
in ADAM10 mRNA expression and activity (sCD23 production). In our studies with the
ADAM10 inhibitor (Figure 46a and b) all the cultures were grown in the presence of both
IL-21 and glutamate and we did not see a change in proliferation. This thus shows that
the change in proliferation caused by IL-21 and glutamate are most likely ADAM10
independent. On the other hand, blocking ADAM10 activity decreased IgE production
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Figure 52: New proposal of the mechanism of how CD23 regulates IgE production.
CD23 has been proposed to regulate IgE, through its binding of CD21 as shown in Figure
2. In our work, we found that CD23 possibly works through an additional mechanism.
We found that CD23 is secreted from B cells in the context of exosomes. In the initial
response as these exosomes contain full length CD23 they can bind IgE/antigen
complexes and increasing the uptake of antigen and antigen presentation by dendritic
cells, which will lead to increased immune reactions, including possible IgE production.
However, as the levels of IgE increase, as shown in Figure 35, less CD23 will be
incorporated into exosomes. Thus once IgE reaches a certain threshold CD23 will be
blocked from entering exosomes. Upon a secondary antigen challenge, this IgE bound
CD23 will bind its antigen and CD23 will once again be internalized and released from
the cell in the context of exosomes.
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showing that the induction of in IgE synthesis by IL-21 and glutamate are possibly
because they increase ADAM10 levels, thus decreasing the levels of membrane bound
CD23. Additionally, it is known that activation of B cells through CD40 signaling causes
increased secretion of exosomes (76). We additionally show that when B cells are
activated by CD40 signaling they also have increased expression of ADAM10 (Figure
44), which is required for CD23 sorting into exosomes (Figure 33a). Thus it is easy to
speculate that activation of B cells leads to increased levels of CD23+-exosome secretion
and shows once again that exosomal CD23 could be involved in enhancing the initial
immune response.
IV. Conclusion and significance
Previously it had been clearly shown that CD23 is involved in allergies (53). This was
done through the use of overexpressing mice and stabilizing antibodies. Additionally, in
work done by Ford et al. (87) it was shown that destabilization CD23 leads to increased
IgE production. As shown in figure 2 this ability of CD23 to control IgE synthesis was
believed to be because of changes in sCD23 binding to CD21. However, in the context
of the mouse system, this theory never completely made sense as mouse sCD23 lacks the
ability to bind CD21. Furthermore, as discussed in the introduction, binding by CD23 of
injected IgE/antigen complexes increases the production of antigen specific IgG by 1000
fold. With the discovery of CD23 being in exosomes, we here propose an additional
model (Figure 52) of how CD23 can have a dual role in both increasing inflammation as
well as down regulating IgE synthesis. We see this model as an enhancement of the
already proposed model. We propose that after an initial antigen challenge, the antigen
will be taken up by dendritic cells and processed. Dendritic cells will then initiate T cell
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activation. This initial activation will cause some IL-4 production. These T cells can
then activate B cells and in the presence of the low level of IL-4 there will be minimal
class switching to IgE. Activation of B cells will also cause increased expression of
ADAM10 (see Figure 44), and increase the CD23+-exosome release. Additionally as we
showed in Figure 27c and 33b, when ligands interact with the stalk region of CD23, the
internalization and incorporation into exosomes of CD23 is increased. These exosomes
can then bind IgE/antigen complexes and increase the uptake of antigen by dendritic
cells, ultimately increasing the immune reaction against the antigen. This model could
explain the data of Ford et al. (87), because the injection of 19G5 would increase the
amount of CD23+-exosomes. The model also gives an explanation to how IgE can
increase inflammation in a mast cell independent matter, as we found in our asthma
studies, although IgE could also possible be binding basophils and have being affect.
Later in the immune reaction, when IgE has reached a certain threshold, most membrane
bound CD23 would be occupied by IgE/antigen complexes and internalization and
exosome incorporation of CD23 would be blocked and provides a negative feedback for
the immune response and IgE production. Overall our data provides a new explanation to
the known enhancement of immunoglobulin and T cell responses by IgE-antigen
complexes. It was known that these responses were dependent on CD23, but not how.
Our work provides a potential explanation. In connection with this, in initial studies with
B cells isolated from allergic patients, we have found that the ADAM10 levels are
increased during allergy season when compared to the levels in non-allergic patients or to
allergy patients out of allergy season (data not shown). The higher ADAM10 would
result in enhanced CD23/exosome secretion and enhance specific IgE production.
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Additionally, in our experiments with the ADAM10 inhibitor we found that
ADAM10 was also important on non-B cells, and we proposed that these cells could
possibly be epithelial cells. Without the cleavage of EFGR ligands, experimental asthma
signs are not exacerbated, as EFGR signaling is required for the down regulation of
Foxa2. In conclusion, these findings show that ADAM10 on both B and non-B cells is
potentially a new target for asthma therapy.
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